go green, go online! jddonline
TRANSCRIPT
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
AAbatacept, randomized double-blind placebo-
controlled clinical trial on efficacy of abatacept costimulatory blockade in alopecia totalis/universalis, 1342
AbobotulinumtoxinA (ABO)in combined treatment for skin rejuvenation
and soft tissue augmentation of aging face, 125
comparing clinical attributes of ABO and onabotulinumtoxinA utilizing Frontalis Rating Scale and Frontalis Activity Measurement Standard, 1148
AC-820 (nalfurafine HCl), randomized-withdrawal phase 3 study on safety and efficacy in hemodialysis and uremic pruritus (CTR), 91
Açai berry, aesthetic benefits of natural ingredients in skin care, s11 (September)
Acitretinassessment of national trends in treatment of
psoriasis, 873depression associated with, 409in dermatology, review of literature on, 772low-dose, efficacy and side effects in psoriasis
(CTR), 95Acne vulgaris
Acanya gel acne therapy available in pump (PP), 1479
adapalene gel in treatment of atrophic acne scars (CTR), 96
advantages of oral contraceptives and spironolactone for women with (DP), 941
CME: demystifying acne algorithms, s5 (June), s24 (June), s26 (June)
combination treatment for moderate-to-severe (CTR), 90
comparing OTC treatment to prescription regimen (CTR), 90, 312
dose-ranging study on safety and efficacy of IDP-107 in (CTR), 426
efficacy and safety of azelaic acid gel 15% in post-inflammatory hyperpigmentation and, 586
Epiduo pediatric acne study (CTR), 90, 312Eucerin launches campaign in Europe and
Asia (PP), 1076
evaluation of clinical improvement in acne scars and active acne in 1540-nm non-ablative fractional laser treatment, 907
evidence-based review on fixed-combination therapy and topical retinoids in, 636
fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI (DP), s6 (December)
Gly-Sal Acne Body Spray (PP), 434importance of vehicles in topical therapy, s17
(June)inflammation in rosacea and acne,
implications for patient care, 614introduction to demystifying acne algorithms
supplement (editorial), s7 (June)isotretinoin does not prolong QT intervals
and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
La Roche-Posay introduces new products (PP), 938
medication choice and associated health care outcomes and costs in acne and acne-related conditions, 766
new information regarding pathogenesis of, 582
patient experience and management of dryness and irritation from treatment, 605
in patients with skin of color, s13 (June)randomized study of dapsone gel 5% in
combination with tazarotene cream 0.1% in, 783
resveratrol-containing gel for (PP), 434rethinking treatment in severe patient, s8
(June)safety and efficacy of clindamycin phosphate
1.2%–benzoyl peroxide 3% fixed-dose combination gel for, 1382
safety and efficacy of micronized tretinoin 0.05% gel in adolescent, 647
self-treatment of mild-to-moderate facial acne with blue light treatment system, 596
strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)
study comparing Aczone plus Differin to Duac
plus Differin in severe facial acne (CTR), 312
study of new drug treatment for (CTR), 687ten tips for treatment in Fitzpatrick skin types
IV–VI (BC), 654why are dermatologists still talking about
acne? because so many people have it, and we are always seeking better ways to manage it (editorial), 575
Actinic cheilitis (AC), treatment by photodynamic therapy with 5-aminolevulinic acid and blue light activation, 1240
Actinic keratoses (AK)comparison of cryotherapy and imiquimod
for, lesion clearance, safety, and skin quality outcomes in, 1432
effect of retinoid pretreatment on outcomes of photodynamic therapy for AK of hand and forearm, 1124
Graceway receives FDA approval for Zyclara Cream 2.5% (PP), 1076
imiquimod cream in combination with cryotherapy in treatment of hypertrophic AK (CTR), 426
long-term sustained complete clearance of AK of face or balding scalp after imiquimod treatment, 165
nonablative 1927 nm fractional resurfacing for (PP), 103
prospective case-based assessment of sequential therapy with topical fluorouracil cream and ALA-PDT for, 372
randomized blinded bilateral intraindividual vehicle-controlled trial of photodynamic therapy with 5-aminolevulinic acid and blue light for AK of upper extremities, 1049
safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
treatment with imiquimod cream followed by photodynamic therapy (CTR), 426
trends in treatment of, 16Acupressure for pruritus in atopic dermatitis
(CTR), 90Adalimumab
Mycobacterium fortuitum infection following adalimumab treatment for psoriasis
2011 SUBJECT INDEXLetters after article titles refer to the following: BC = Brief Communication; CR = Case Reports; CTR = Clinical Trial Review; DP = DermPearls; NVR = News, Views, and Reviews; PP = Pipeline Previews; RR = Resident Rounds; RS = Resident Spotlight
As part of the JDD green initiative, starting in 2009, the author and subject indexes will be published exclusively online. In previous years these have been printed in the December Issue, but for your convenience and for
environmental consciousness, the indexes will now be available electronically.
Go Green, Go Online!
JDDonline.com
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
and subsequent complication-free treatment with alternate TNF-a blockers (CR), 914
and narrowband ultraviolet B light phototherapy for moderate to severe psoriasis, 366
open-label prospective cohort pilot study on efficacy and safety of etanercept in moderate to severe plaque psoriasis in patients without adequate response to, 396
treatment of recalcitrant generalized granuloma annulare with (CR), 1466
Adapaleneadapalene gel 0.3% in atrophic acne scars
(CTR), 96Epiduo pediatric acne study (CTR), 90, 312rethinking treatment of acne in severe patient,
s8 (June)study comparing Aczone plus Differin to Duac
plus Differin in severe facial acne (CTR), 312
in topical monotherapy for acne, compared to fixed-combination therapy, 636
Adherence to treatmentin once-daily therapy with sertaconazole
nitrate for interdigital tinea pedis, 1135
patient experience and management of dryness and irritation from acne treatment affecting, 605
in topical rosacea therapy, vehicle formulations affecting, 627
AEB071, dose finding study assessing psoriasis area and severity index in plaque psoriasis (CTR), 92
Agingclinical evidence for activity of
tetrahydroxypropyl ethylenediamine (THPE) as new anti-aging active cosmetic, 1102
combined treatment for skin rejuvenation and soft-tissue augmentation of aging face, 125
dermal fillers in skin of color population, 494evolution of injectable poly-L-lactic acid from
correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001
guide to temporal fossa augmentation with small gel particle hyaluronic acid dermal filler in, 673
multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352
prospective randomized trial on effects of fluence settings in Er:YAG micropeel for facial photoaging, 179
safety and efficacy of calcium hydroxylapatite for rejuvenation of aging hand, 47
tower technique for injection of hyaluronic acid fillers in, 1277
AIDS. See HIV infection and AIDSAIN457, dose-ranging study in moderate-to-
severe chronic plaque-type psoriasis (CTR), 93
Albert Einstein College of Medicine Unified Division of Dermatology
eruptive plexiform schwannomas in child with neurofibromatosis I (RR), 1210
intralymphatic histiocytosis associated with orthopedic implants (RR), 1208
program spotlight on Residency Program
(RR), 1122sound-alike and look-alike terms in
dermatology (RR), 1196Alefacept for nephrogenic systemic fibrosis (CR),
922Alexandrite laser
comparison of sequential treatment with diode and alexandrite lasers versus alexandrite laser alone in hirsutism, 1255
treating lentigines in Asian patients with Q-switched Alexandrite laser (DP), s14 (December)
Aloe veraaesthetic benefits of natural ingredients in
skin care, s11 (September)in atopic dermatitis and other inflammatory
skin diseases, s6 (September)Aloesin, aesthetic benefits of natural ingredients
in skin care, s11 (September)Alopecia
approvals, long-term safety data, cancer risk, and treatment options in androgenetic alopecia in women (NVR), 98
dutasteride versus placebo and finasteride in men with androgenetic alopecia (CTR), 936
novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution (CR), 795
randomized double-blind placebo-controlled clinical trial on efficacy of abatacept costimulatory blockade in alopecia totalis/universalis, 1342
role of inflammation and immunity in pathogenesis of androgenetic alopecia, 1404
safety and efficacy of clobetasol propionate 0.05% emollient foam in (CTR), 1077
safety and efficacy study of bimatoprost in women with female pattern hair loss (CTR), 936
scalp hyperkeratosis and alopecia in children of color, 511
START (Swiss Taxotere Alopecia Prevention Trial) (CTR), 936
Amazingel compared to other polyacrylamide hydrogels, 1370
AMG 157, safety study in healthy subjects and subjects with atopic dermatitis (CTR), 313, 687
Aminolevulinic acid (ALA)effect of retinoid pretreatment on outcomes
of ALA-PDT for actinic keratosis of hand and forearm, 1124
preliminary results of hidradenitis suppurativa treatment with ALA-PDT, 381
prospective case-based assessment of sequential therapy with topical fluorouracil cream and ALA-PDT for actinic keratosis, 372
randomized blinded bilateral intraindividual vehicle-controlled trial of ALA-PDT and blue light for actinic keratoses of upper extremities, 1049
safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
severe cutaneous reaction to ALA-PDT with blue light (CR), 1057
treatment of actinic cheilitis by ALA-PDT and blue light activation, 1240
Amiodarone, Q-switched laser treatment of amiodarone pigmentation (CR), 1316
Ammonium lactate emollient foam vehicle, salicylic acid 6% in, for scalp psoriasis, 270
Anakinraeffective for severe Muckle-Wells syndrome
(PP), 214pilot study in severe atopic dermatitis (CTR),
313Anal cancer, FDA approves Gardasil to prevent
(PP), 325Anal fissures, FDA approval of Rectiv for pain
associated with (PP), 939Androgens, decrease of insulin growth factor-1
as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793
Anti-inflammatory agentscutaneous reactions to non-steroidal anti-
inflammatory drugs, 1160in natural ingredients, s12 (September)randomized study of dapsone gel 5% in
combination with tazarotene cream 0.1% in acne vulgaris, 783
Antimicrobial drugsantibiotic resistance: an editorial review with
recommendations, 724FDA approves Ceftaroline for MRSA (PP), 104recent advances and future directions in
medical management of skin disease, 28
rethinking treatment of acne in severe patient, s8 (June)
Antioxidantsassessment of antioxidative capacity kinetics
of topical antioxidants, 262complementary antioxidant function of
caffeine and green tea polyphenols in normal human skin fibroblasts, 753
green tea extract protects human skin fibroblasts from reactive oxygen species induced necrosis, 1096
in natural ingredients, s11 (September)Apremilast
open label pilot study in rosacea (CTR), 313phase 2 open-label investigator-initiated study
of safety and efficacy in recalcitrant contact or atopic dermatitis (RS), 928
study to evaluate safety and effectiveness of oral apremilast (CC-10004) in moderate-to-severe plaque psoriasis (CTR), 1487
Aquamid compared to other polyacrylamide hydrogels, 1370
Aquaphor Healing Ointment compared to prescription barrier creams in mild-to-moderate atopic dermatitis of children, 531
Arbutin, aesthetic benefits of natural ingredients in skin care, s11 (September)
Arrhythmias, isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
L-Ascorbic acid, evaluation of prescription strength 4% hydroquinone/10% L-ascorbic acid treatment system for photodamage in normal to oily skin, 1455
Asian patientscommunity-based survey of skin conditions
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
and concerns in South Asian Americans, 524
treating lentigines with Q-switched Alexandrite laser in (DP), s14 (December)
ASP015K, study to explore efficacy and safety in moderate-to-severe psoriasis (CTR), 93, 315
Atopic dermatitis (AD)acupressure for pruritus in (CTR), 90bilateral comparison study of pimecrolimus
cream 1% and medical device cream in, 735
bilateral comparison study of pimecrolimus cream 1% and medical device emollient foam in, 666
comparing Cetaphil Restoraderm System versus standard skin care in infants with (CTR), 1486
comparison of OTC moisturizer and prescription barrier creams in mild-to-moderate AD of children, 531
effects of novel fluocinonide cream formulation on skin barrier function in, 171
efficacy, safety, and tolerability of topical nalmefene for pruritus in, 853
efficacy and safety of different concentrations of ZK245186 in (CTR), 313
efficacy of fluocinonide cream 0.1% in reducing itch in (CTR), 1486
natural ingredients for skin care and treatment in, s6 (September)
new body moisturizer increases skin hydration and improves AD symptoms in children and adults, 714
pediatric longitudinal evaluation on long-term safety of Protopic Ointment for (CTR), 1217
phase 2 open-label investigator-initiated study of safety and efficacy of apremilast in recalcitrant contact or atopic dermatitis (RS), 928
pilot study of Anakinra in severe AD (CTR), 313
recent advances in treatment of, 28safety study of AMG 157 in healthy subjects
and subjects with AD (CTR), 313, 687
sequential ascending dose study on safety and tolerability of REGN668 in (CTR), 314
stratum corneum abnormalities in, s9 (October)
Autoimmune conditionsblisters in (RR), 491bullous pemphigoid after herpes zoster
vaccine administration (CR), 1328effectiveness of topical tacrolimus for vitiligo
in, 507highlights of common autoimmune
connective tissue diseases (RR), 1314
Avotermin in keloids (NVR), 550Axillary hyperhidrosis, same-patient prospective
comparison and literature review of Botox versus Dysport for (CR), 1013
Azelaic acidefficacy and safety of azelaic acid gel
15% in post-inflammatory hyperpigmentation and acne, 586
in topical rosacea therapy, vehicle formulations for, 627
Azficel-TFDA approval of Fibrocell Science LAVIV (PP),
939in nasolabial folds and wrinkles (PP), 325, 939
BB cell lymphoma, diffuse large, associated with
biologic and other investigational agents in psoriasis (CR), 80
Barrier creams, prescription, compared to OTC moisturizer for mild-to-moderate atopic dermatitis in children, 531
Barrier function of skin. See Skin barrier functionBasal cell carcinoma (BCC)
electronic brachytherapy for treatment of (CTR), 206
Genentech submits New Drug Application to FDA for (PP), 1340
study on efficacy and safety of GDC-0449 in (CTR), 206
ulcerated nodular nasal BCC successfully treated with imiquimod 5% cream (letter to the editor), 240
Belimumab, FDA approves Benlysta for lupus erythematosus (PP), 806
Benzocaine, methemoglobinemia risk from benzocaine topical products (PP), 684
Benzoyl peroxideAcanya gel acne therapy available in pump
(PP), 1479in combination treatment for moderate-to-
severe acne (CTR), 90Epiduo pediatric acne study (CTR), 90, 312in fixed-combination therapy for acne,
compared to retinoid monotherapy, 636
patient experience and management of dryness and irritation from acne treatment with, 605
rethinking treatment of acne in severe patient, s8 (June)
safety and efficacy of clindamycin phosphate 1.2%–benzoyl peroxide 3% fixed-dose combination gel for acne vulgaris, 1382
study comparing Aczone plus Differin to Duac plus Differin in severe facial acne (CTR), 312
Betamethasone dipropionateLEO Pharma launches $0 copay program
for Taclonex plaque psoriasis treatments (PP), 683
topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in moderate-to-severe plaque psoriasis, 878
Bexarotene, study evaluating two dose levels of Targretin capsules in refractory cutaneous T-cell lymphoma (CTR), 209
Bicillin-LA versus placebo for chronic plaque-type psoriasis unresponsive to topical medications (CTR), 317
Bimatoprostnovel treatment of female-pattern
androgenetic alopecia with injected bimatoprost 0.03% solution (CR), 795
safety and efficacy in women with female pattern hair loss (CTR), 936
Bio-Alcamid compared to other polyacrylamide hydrogels, 1370
Bioflavanoids, randomized placebo-controlled
double-blind study on efficacy of citrus bioflavanoid blend in senile purpura, 718
Biologicsdiffuse large B-cell lymphoma associated with
biologic and other investigational agents in psoriasis (CR), 80
impact on disease and treatment burden of psoriasis, 189
Biopsy diagnosisclinical clues and patterns to help distinguish
cutaneous metastases (NVR), 678, 930
comparison of diagnostic and biopsy/referral sensitivity to melanoma between dermatologists and MelaFind (RS), 1078
Bladder cancerclinical clues and patterns in biopsy diagnosis
of cutaneous metastases of (NVR), 678, 930
review of chemopreventative effects of oral retinoids for, 1292
Blisters, autoimmune-mediated (RR), 491Blue light
randomized blinded bilateral intraindividual vehicle-controlled trial of photodynamic therapy with 5-aminolevulinic acid and blue light for actinic keratoses of upper extremities, 1049
safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
self-treatment of mild-to-moderate facial acne with blue light treatment system, 596
severe cutaneous reaction to photodynamic therapy with (CR), 1057
treatment of actinic cheilitis by photodynamic therapy with 5-aminolevulinic acid and blue light activation, 1240
Botanical productscomparative study of safety and efficacy of
75% mulberry extract oil versus placebo as topical treatment for melasma, 1025
cosmeceutical and nutraceutical horizons, 24evaluation of moisturizing effect of
methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensiometry methods, 1116
randomized double-blind petrolatum-controlled study on efficacy of oregano extract ointment in wound healing, 1168
Botulinum toxinAllergan cell-based assay for BOTOX (PP), 938in combined treatment for skin rejuvenation
and soft-tissue augmentation of aging face, 125
comparing clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA using Frontalis Rating Scale and Frontalis Activity Measurement Standard, 1148
cosmeceutical and nutraceutical horizons, 24FDA approves Botox for chronic migraine
(PP), 104FDA approves Xeomin (incobotulinumtoxinA)
for glabellar lines (PP), 1076Frontalis Activity Measurement Standard
as novel contralateral method for
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
assessing botulinum neurotoxin type-A activity, 968
in keloid management (NVR), 549long-term efficacy and potencies of botulinum
toxin A and B (PP), 324rapid onset of response and patient-reported
outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines, 39
same-patient prospective comparison and literature review of Botox versus Dysport for primary axillary hyperhidrosis (CR), 1013
Brachytherapy, electronic, for non-melanoma skin cancer treatment (CTR), 206
Breast cancerclinical clues and patterns in biopsy diagnosis
of cutaneous metastases (NVR), 678, 930
review of chemopreventative effects of oral retinoids for, 1292
Breast reconstructive surgery, case report of pyoderma gangrenosum following treated with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545
Briakinumab withdrawal from FDA review (PP), 435
Brief Communications (BC)assessor-blinded study of metabolic
syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared with age-matched population of children with warts, 900
CD70 and Th17 are involved in human contact sensitivity, 1192
community-based survey of skin conditions and concerns in South Asian Americans, 524
decrease of insulin growth factor-1 as novel mechanism for anti-androgen effect of isotretinoin and its reported association with depression in some cases, 793
efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sézary syndrome, 403
ten tips for treating acne vulgaris in Fitzpatrick skin types IV–VI, 654
Broward General Medical Center Residency Training Program
autoimmune-mediated blisters (for the Boards) (RR), 491
case report on pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545
program spotlight on (RR), 467Bupivacaine hydrochloride, Sagent
Pharmaceuticals announces FDA approval of bupivacaine hydrochloride injection (PP), 1478
Burdock, evaluation of moisturizing effect of methanolic extract incorporated into cream bases using impedance and extensiometry methods, 1116
Burnsappearance of burn scars after fractional
carbon dioxide laser treatment (CTR), 96
chemical burn from povidone-iodine (CR), 414multiple facial burns with new Thermage CPT
system (CR), 1320
CCaffeine, complementary antioxidant function of
caffeine and green tea polyphenols in normal human skin fibroblasts, 753
Calcinosis cutis, ulcerative, novel treatment for, 1042
Calciphylaxis, evaluation of efficacy of lanthanum carbonate in (CTR), 1342
CalcipotrieneFDA approves Sorilux foam (PP), 103LEO Pharma launches $0 copay program
for Taclonex plaque psoriasis treatments (PP), 683
topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in moderate-to-severe plaque psoriasis, 878
Calcitriolmulti-center open-label study on safety and
efficacy of sequential treatment regimen of clobetasol propionate spray followed by calcitriol ointment in plaque psoriasis, 158
Yin-Yang strategy in new effective repeatable sequential therapy for psoriasis, 831
Calcium hydroxylapatite, management of impending necrosis associated with soft tissue filler injections (CR), 1007
Cardiovascular disease riskmetabolic syndrome and surrogate markers
of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900
psoriasis drugs not linked to increased heart risks (PP), 1215
Case Reports (CR)alefacept therapy for nephrogenic systemic
fibrosis, 922bullous pemphigoid after herpes zoster
vaccine administration, 1328case of lichen planus following Tdap
vaccination, 1067central serous chorioretinopathy associated
with topical corticosteroids in psoriasis, 918
chemical burn from povidone-iodine, 414chloracne-like drug eruption associated with
sorafenib, 1331diffuse large B-cell lymphoma associated with
biologic and other investigational agents in psoriasis, 80
erythema multiforme-like drug reaction to sorafenib, 1462
fatal cutaneous strongyloidiasis as side effect of mycophenolate mofetil in pemphigus foliaceus in immunocompromised patient, 418
fixed drug eruption associated with iohexol intravenous contrast media, 802
levamisole induced necrosis of skin and neutropenia following intranasal cocaine use: a newly recognized syndrome, 1204
management of impending necrosis associated with soft tissue filler
injections, 1007metallic taste as side effect of topical
fluorouracil, 1201modified Tripier flap for lateral eyelid
reconstruction, 199Mohs micrographic surgery for cutaneous
lymphadenoma, 1324multiple facial burns with new Thermage CPT
system, 1320Mycobacterium fortuitum infection following
adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-a blockers, 914
novel KRT14 mutation in epidermolysis bullosa simplex with mottled pigmentation, 926
novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution, 795
pigmentary changes in patient treatment with imatinib, 1062
post-herpetic itch resolved with gabapentin, 85
Q-switched laser treatment of amiodarone pigmentation, 1316
regression of internal melanoma metastases after topical application of imiquimod, 302
rituximab dosing in refractory pemphigus vulgaris in adolescent male, 202
same-patient prospective comparison and literature review of Botox versus Dysport for primary axillary hyperhidrosis, 1013
severe cutaneous reaction to photodynamic therapy with blue light, 1057
sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in hepatocellular carcinoma, 308
tamoxifen-induced hirsutism, 799tattoo sites and psoriasis, 1199treatment of peristomal pyoderma
gangrenosum with topical crushed dapsone, 1059
treatment of recalcitrant generalized granuloma annulare with adalimumab, 1466
vesiculobullous variant of adult T-cell leukemia/lymphoma in a Caribbean émigré, 1469
CC-10004 for prurigo nodularis (CTR), 91CD70 and TH17 involvement in human contact
sensitivity (BC), 1192CD07805/47 topical gel, phase 3 efficacy and
study in facial erythema associated with rosacea (CTR), 1216
Ceramidebilateral comparison study of pimecrolimus
cream 1% and ceramide-hyaluronic acid emollient foam in atopic dermatitis, 666
ceramide-containing barrier repair cream compared to OTC moisturizer for mild-to-moderate atopic dermatitis in children, 531
Cetaphil Restoraderm System compared to standard skin care in infants with atopic dermatitis (CTR), 1486
Chamomile in atopic dermatitis and other inflammatory skin diseases, s6 (September)
Cheilitis, actinic, treatment by photodynamic
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
therapy with 5-aminolevulinic acid and blue light activation, 1240
Chemical burn from povidone-iodine (CR), 414Chemical peels
in combined treatment for skin rejuvenation and soft tissue augmentation of aging face, 125
comparison of 1% tretinoin peeling versus 70% glycolic acid peeling in female patients with melasma, 1439
Chemoprevention, review of chemopreventative effects of oral retinoids for internal neoplasms, 1292
Chemotherapy, START (Swiss Taxotere Alopecia Prevention Trial) (CTR), 936
Children. See Pediatric dermatologyChitosan, treatment efficacy of triple bandage
compression and chitosan gel in venous leg ulcers, 75
Chloracne-like drug eruption associated with sorafenib (CR), 1331
Chorioretinopathy, central serous, associated with topical corticosteroids in psoriasis (CR), 918
Citrus bioflavanoid blend, randomized placebo-controlled double-blind study on efficacy in senile purpura, 718
Cleansing product in novel rosacea treatment system, investigator-blind randomized parallel-group study on, 1179
ClindamycinAcanya gel acne therapy available in pump
(PP), 1479in combination treatment for moderate-to-
severe acne (CTR), 90in fixed-combination therapy for acne,
compared to retinoid monotherapy, 636
patient experience and management of dryness and irritation from acne treatment with, 605
safety and efficacy of clindamycin phosphate 1.2%–benzoyl peroxide 3% fixed-dose combination gel for acne vulgaris, 1382
study comparing Aczone plus Differin to Duac plus Differin in severe facial acne (CTR), 312
Clinical Trial Reviews (CTR)acupressure for pruritus in atopic dermatitis,
90adapalene gel in treatment of atrophic acne
scars, 96Bicillin-LA versus placebo for chronic plaque-
type psoriasis unresponsive to topical medications, 317
burn scar appearance after fractional carbon dioxide laser treatment, 96
CC-10004 for prurigo nodularis, 91clinical trial of Dermacorder for detecting
malignant skin lesions, 317combination treatment for moderate-to-
severe acne, 90comparing Aczone plus Differin to Duac plus
Differin in severe facial acne, 312comparing Cetaphil Restoraderm System
versus standard skin care in infants, 1486
comparing OTC acne treatment to prescription regimen, 90, 312
comparison of elective lymph node treatment versus clinical observation in absence of palpable lymph nodes in high risk squamous cell carcinoma,
207comparison of retinol 1.0% and tretinoin
0.02% in moderate-to-severe photodamage and wrinkles, 1217
CP-690-550 ointment for chronic plaque psoriasis, 316
dapsone gel 5% for dermatitis herpetiformis, 314
dasatinib in locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery, 208
dasatinib in unresectable or metastatic squamous cell skin cancer or RAI stage 0-1 chronic lymphocytic leukemia, 207
dose finding study of AEB071 assessing psoriasis area and severity index in plaque psoriasis, 92
dose-ranging study of AIN457 in moderate-to-severe chronic plaque-type psoriasis, 93
dose-ranging study on safety and efficacy of IDP-107 in acne vulgaris, 426
dutasteride versus placebo and finasteride in men with androgenetic alopecia, 936
effects of pulsed-dyed laser on scar formation, 96
efficacy and safety of different concentrations of ZK245186 in atopic dermatitis, 313
efficacy and side effects of low-dose acitretin in psoriasis, 95
efficacy of fluocinonide cream 0.1% in reducing itch in atopic dermatitis, 1486
electronic brachytherapy for non-melanoma skin cancer treatment, 206
Epiduo pediatric acne study, 90, 312evaluation of efficacy of lanthanum carbonate
in calciphylaxis, 1342gemcitabine and pemetrexed disodium in
advanced mycosis fungoides or Sézary syndrome, 210
imatinib in mucosal or acral/lentiginous melanoma, 208
imiquimod cream in combination with cryotherapy in treatment of hypertrophic actinic keratosis, 426
in vivo confocal microscopy of cutaneous neoplasms and normal skin, 318
lenalidomide in AIDS-related Kaposi sarcoma, 210
lenalidomide in relapsed mycosis fungoides/Sézary syndrome, 209
liposomal daunorubicin in HIV-related Kaposi’s sarcoma, 212
long-term study to evaluate safety and tolerability of CP-690,550 in moderate-to-severe chronic plaque psoriasis, 94
melanoma detection by oblique-incidence optical spectroscopy, 318
one-year study on efficacy and safety of CP-690,550 for moderate-to-severe chronic plaque psoriasis, 688
open label pilot study of Apremilast in rosacea, 313
pediatric longitudinal evaluation on long-term safety of Protopic Ointment for atopic dermatitis, 1217
phase 3 efficacy and study of CD07805/47 topical gel in facial erythema
associated with rosacea, 1216phase 2 trial of erlotinib prior to surgery or
radiation in squamous cell cancer of skin, 207
pilot study of Anakinra in severe atopic dermatitis, 313
PTC299 in HIV-related Kaposi sarcoma, 211randomized double-blind placebo-controlled
clinical trial on efficacy of abatacept costimulatory blockade in alopecia totalis/universalis, 1342
randomized double-blind placebo-controlled multi-center trial of zinc for herpes simplex labialis, 1343
randomized study of PH-10 for psoriasis, 315randomized trial of intravenous
immunoglobulin with or without cyclophosphamide in pemphigus, 1077
randomized-withdrawal phase 3 study on safety and efficacy of nalfurafine HCl (AC-820) in hemodialysis and uremic pruritus, 91
safety and efficacy of bimatoprost in women with female pattern hair loss, 936
safety and efficacy of clobetasol propionate 0.05% emollient foam in alopecia, 1077
safety and efficacy of LEO 80185 topical suspension in adolescents with scalp psoriasis, 95
safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis, 1216
safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis, 313, 687
sequential ascending dose study on safety and tolerability of REGN668 in atopic dermatitis, 314
sorafenib and temsirolimus in metastatic, recurrent, or unresectable melanoma, 207
spectral diagnosis of cutaneous malignancy, 318
START (Swiss Taxotere Alopecia Prevention Trial), 936
study evaluating two dose levels of Targretin capsules in refractory cutaneous T-cell lymphoma, 209
study of clinical activity, safety, and tolerability of SRT2104 in moderate-to-severe plaque-type psoriasis, 92, 314
study of human monoclonal antibody (zanolimumab) to treat mycosis fungoides and Sézary syndrome, 1077
study of LY2439821 in moderate-to-severe psoriasis, 94
study of new drug treatment for acne, 687study of total skin electron beam therapy in
stage IB-IIIA mycosis fungoides, 209study of ultrasonography with elastography in
skin neoplasms, 319study on efficacy and safety of GDC-0449 in
operable basal cell carcinoma, 206study to assess VB-201 in psoriasis, 93, 316study to evaluate safety and effectiveness
of oral apremilast (CC-10004) in moderate-to-severe plaque psoriasis, 1487
study to explore efficacy and safety of ASP015K in moderate-to-severe
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
psoriasis, 93, 315T cell repertoire analysis of immune mediated
skin diseases, 936topical imiquimod with Nd:YAG laser to tattoo
removal, 1342treatment of actinic keratoses of face with
imiquimod cream followed by photodynamic therapy, 426
treatment of notalgia paresthetica with Xeomin, 91
treatment of surgical scars using pulsed dye laser, 96, 1216
use of etanercept as sole treatment for grade I acute graft versus host disease, 1487
Clobetasol propionatemulti-center open-label study on safety and
efficacy of sequential treatment regimen of clobetasol propionate spray followed by calcitriol ointment in plaque psoriasis, 158
open-label study on treatment of mild-to-moderate chronic hand dermatitis with 0.05% emulsion formulation foam, 1398
randomized controlled trial on 0.05% spray for moderate-to-severe plaque psoriasis of scalp, 885
safety and efficacy of 0.05% emollient foam in alopecia (CTR), 1077
Yin-Yang strategy in new effective repeatable sequential therapy for psoriasis, 831
Cocaine, levamisole induced necrosis of skin and neutropenia following intranasal cocaine use: a newly recognized syndrome (CR), 1204
Coffeeberryaesthetic benefits of natural ingredients in
skin care, s12 (September)Stiefel/GSK introduces Illumuminesse
Brightening Complex (PP), 938Colchicine
in keloid management (NVR), 549treatment of chronic urticaria with, 1423
Collagen topical gel, Cardium Therapeutics announces FDA 510(k) clearance for Excellagen (PP), 1478
Colorectal cancer, clinical clues and patterns in biopsy diagnosis of cutaneous metastases (NVR), 678, 930
Complement activation by Mycobacterium leprae, 274
Complexion blending, safety and efficacy cosmetic laser treatments in skin of color, 36
Compression bandage and chitosan gel in treatment of venous leg ulcers, 75
Confocal microscopyof cutaneous neoplasms and normal skin
(CTR), 318pilot study using reflectance confocal
microscopy in assessment of novel formulation for melasma, 1260
Contact dermatitisCD70 and Th17 in (BC), 1192phase 2 open-label investigator-initiated study
of safety and efficacy of apremilast in recalcitrant contact or atopic dermatitis (RS), 928
Continuing medical educationdemystifying acne algorithms, s5 (June), s24
(June), s26 (June)identifying natural ingredients and their use
in skin care, s4 (September), s21
(September), s22 (September)Contraceptives, oral, advantages of oral
contraceptives and spironolactone for women with acne (DP), 941
Contrast mediaalefacept therapy for nephrogenic systemic
fibrosis associated with (CR), 922fixed drug eruption associated with iohexol
intravenous contrast media (CR), 802
Copper and zinc in natural therapies for hyperpigmentation, s18 (September)
Corrugator supercilii muscle, terminal nerve ablation using novel thread technique for treatment of hyperdynamic vertical glabellar furrows, 762
Corticosteroidscentral serous chorioretinopathy associated
with topical corticosteroids in psoriasis (CR), 918
FDA approval of Rituxan with corticosteroids for severe vasculitis (PP), 683
multi-center open-label study on safety and efficacy of sequential treatment regimen of clobetasol propionate spray followed by calcitriol ointment in plaque psoriasis, 158
reported adverse effects of isotretinoin and (RR), 287
Yin-Yang strategy in new effective repeatable sequential therapy for psoriasis, 831
Cosmetic dermatologyAlma Lasers introduces iPixel fractional
ablative technology (PP), 805assessment of antioxidative capacity kinetics
of cosmetic formulation, 262clinical evidence for activity of
tetrahydroxypropyl ethylenediamine (THPE) as new anti-aging active cosmetic, 1102
combined treatment for skin rejuvenation and soft-tissue augmentation of aging face, 125
corrugator supercilii muscle terminal nerve ablation using novel thread technique for treatment of hyperdynamic vertical glabellar furrows, 762
cosmeceutical and nutraceutical horizons, 24cosmetic treatments on skin of color, a unique
challenge (editorial), s4 (December)dermal fillers in skin of color population, 494efficacy and tolerability of new monophasic
double-crosslinked hyaluronic acid filler for deep lines and wrinkles, 134
guide to temporal fossa augmentation with small gel particle hyaluronic acid dermal filler, 673
open-label pilot study on effectiveness and safety of hyaluronic acid in lip augmentation, 145
prospective randomized trial on effects of fluence settings in Er:YAG micropeel for facial photoaging, 179
rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines, 39
Safe Cosmetics Act of 2011 (PP), 1215safety and efficacy of cosmetic laser
treatments for skin of color, 35Cost considerations
increased prevalence of psychiatric disorders
and health care-associated costs in moderate-to-severe psoriasis, 843
medication choice and associated health care outcomes and costs in acne and acne-related conditions, 766
CP-690,550for chronic plaque psoriasis (CTR), 316long-term study to evaluate safety and
tolerability in moderate-to-severe chronic plaque psoriasis (CTR), 94
one-year study on efficacy and safety for moderate-to-severe chronic plaque psoriasis (CTR), 688
Cryotherapycompared to imiquimod for actinic keratoses,
lesion clearance, safety, and skin quality outcomes in, 1432
comparison of dimethyl ether and propane to liquid nitrogen in cryosurgical treatment of warts, case report and review of literature on, 1174
imiquimod cream in combination with, in treatment of hypertrophic actinic keratosis (CTR), 426
Cutis laxa, acquired, cutaneous hypersensitivity during selective serotonin reuptake inhibitor therapy resulting in (RR), 215
Cyclophosphamide, randomized trial of intravenous immunoglobulin with or without cyclophosphamide in pemphigus (CTR), 1077
DDapsone
in dermatitis herpetiformis (CTR), 314randomized study of dapsone gel 5% in
combination with tazarotene cream 0.1% in acne vulgaris, 783
study comparing Aczone plus Differin to Duac plus Differin in severe facial acne (CTR), 312
treatment of peristomal pyoderma gangrenosum with topical crushed dapsone (CR), 1059
Dasatinibin locally advanced or metastatic mucosal
melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery (CTR), 208
in unresectable or metastatic squamous cell skin cancer or RAI stage 0-1 chronic lymphocytic leukemia (CTR), 207
Daunorubicin, liposomal, in HIV-related Kaposi’s sarcoma (CTR), 212
Depressionassociated with acitretin, 409decrease of insulin growth factor-1 as novel
mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793
Dermabrasion, treatment of vitiligo with melanocyte-keratinocyte cell suspension versus dermabrasion only in pilot study with 12-month follow-up, 1032
Dermacorder, clinical trial on detecting malignant skin lesions with (CTR), 317
Dermal fillersclinical pearls for dermal filler enhancement
in patients with skin of color (DP), s23 (December)
in combined treatment for skin rejuvenation and soft tissue augmentation of aging face, 125
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
commentary on rheological evaluation of the physical properties of hyaluronic acid dermal fillers (letter to the editor), 964
cosmeceutical and nutraceutical horizons, 24efficacy and tolerability of new monophasic
double-crosslinked hyaluronic acid filler for deep lines and wrinkles, 134
guide to temporal fossa augmentation with small gel particle hyaluronic acid dermal filler, 673
open-label pilot study on effectiveness and safety of hyaluronic acid in lip augmentation, 145
rheological evaluation of physical properties of hyaluronic acid dermal fillers, 974
safety and efficacy of calcium hydroxylapatite for rejuvenation of aging hand, 47
in skin of color population, 494tower technique for injection of hyaluronic
acid fillers in, 1277DermaPACE device for diabetic foot ulcers (PP),
325Dermatitis
atopic. See Atopic dermatitis (AD)CD70 and Th17 in contact dermatitis (BC), 1192dapsone gel 5% for dermatitis herpetiformis
(CTR), 314managing epidermal barrier function in
treatment of dermatoses, s13 (October)
open-label study of safety and efficacy of sertaconazole nitrate in seborrheic dermatitis, 895
open-label study on treatment of mild-to-moderate chronic hand dermatitis with clobetasol propionate 0.05% emulsion formulation foam, 1398
phase 2 open-label investigator-initiated study of safety and efficacy of apremilast in recalcitrant contact or atopic dermatitis (RS), 928
Dermatofibrosarcoma protuberans, malignancy arising with cutaneous tattoo, 837
Dermatology education. See Resident Rounds (RR); Training
Dermatomyositis, fulminant, with flagellate erythema (RR), 902
Dermoscopy, multispectral digital, computer-based analysis in, 21
DermPearls (DP)advantages of oral contraceptives and
spironolactone for women with acne, 941
best practices and evidence-based use of 800 nm diode laser for pseudofolliculitis barbae in skin of color, s20 (December)
clinical pearls for dermal filler enhancement in patients with skin of color, s23 (December)
diode 810 nm laser as safe, effective modality to meet a growing population need, s8 (December)
fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI, s6 (December)
importance of before and after photographs to practice, 940
laser hair removal in ethnic skin, principles and practical aspects of, s17 (December)
laser hair removal pearls in skin of color, s12
(December)novel 0.65 millisecond pulsed 1064 nm
laser to treat skin of color without skin cooling or anesthetics, s10 (December)
strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color, s25 (December)
treating lentigines in Asian patients with Q-switched Alexandrite laser, s14 (December)
Devices and equipmentAlma Lasers introduces iPixel fractional
ablative technology (PP), 805clinical trial of Dermacorder for detecting
malignant skin lesions (CTR), 317CoreRx Pharmaceuticals introduces
Xcelodose micro-dosing system (PP), 1478
dermaPACE device for diabetic foot ulcers (PP), 325
Ellman International introduces Pellevé Wrinkle Reduction System to European market (PP), 938
FDA clearance of EndyMed Fractional Skin Resurfacing Applicator (PP), 435
FDA gives provisional approval to MelaFind device (PP), 1340
FDA grants marketing clearance for HairMax Dual 12 home-use laser phototherapy device (PP), 1341
FDA panel votes in favor of MelaFind skin cancer detection device (PP), 213
multiple facial burns with new Thermage CPT system (CR), 1320
self-treatment of mild-to-moderate facial acne with blue light treatment system, 596
spectral diagnosis probe in cutaneous malignancy detection (CTR), 318
Syneron devices at 22nd world Congress of Dermatology (PP), 805
Dexpanthenol in atopic dermatitis and other inflammatory skin diseases, s6 (September)
Diabetes mellitus, dermaPACE device for diabetic foot ulcers (PP), 325
Diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis (CR), 80
Dimethyl ether and propane compared to liquid nitrogen in cryosurgical treatment of warts, case report and review of literature on, 1174
Diode laserbest practices and evidence-based use of 800
nm diode laser for pseudofolliculitis barbae in skin of color (DP), s20 (December)
comparison of high-fluence single-pass diode laser to low-fluence multiple-pass diode laser for hair reduction with 18 months of follow up, 62
comparison of sequential treatment with diode and alexandrite lasers versus alexandrite laser alone in hirsutism, 1255
diode 810 nm laser as safe, effective modality to meet a growing population need (DP), s8 (December)
Discoid lupus, is chronic cutaneous discoid lupus protective against severe renal disease in systemic lupus erythematosus?, 1413
Doxycyclinecompared to minocycline for management of
acne (letter to the editor), 965, 966rethinking treatment of acne in severe patient,
s8 (June)self-reported treatment impressions and
satisfaction of papulopustular rosacea patients treated with doxycycline USP 40 mg capsules, 1376
Drug calendar, electronic, in cutaneous drug eruptions, 1430
Drug reactions/toxicitycase of lichen planus following Tdap
vaccination (CR), 1067causes and clinical courses of drug-induced
urticaria, 1019central serous chorioretinopathy associated
with topical corticosteroids in psoriasis (CR), 918
chemical burn from povidone-iodine (CR), 414chloracne-like drug eruption associated with
sorafenib (CR), 1331clinical trial safety and mortality analysis
of etanercept across approved indications, 289
creation of electronic drug calendar in drug hypersensitivity, 1430
cutaneous hypersensitivity during selective serotonin reuptake inhibitor therapy resulting in acquired cutis laxa (RR), 215
cutaneous reactions to non-steroidal anti-inflammatory drugs, 1160
erythema multiforme-like drug reaction to sorafenib (CR), 1462
fixed drug eruption associated with iohexol intravenous contrast media (CR), 802
iododerma following radioactive iodine ablation of thyroid for Graves disease (RR), 1070
isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
levamisole induced necrosis of skin and neutropenia following intranasal cocaine use: a newly recognized syndrome (CR), 1204
levamisole-induced retiform purpura (RR), 217metallic taste as side effect of topical
fluorouracil (CR), 1201methemoglobinemia risk from benzocaine
topical products (PP), 684pigmentary changes in patient treatment with
imatinib (CR), 1062Q-switched laser treatment of amiodarone
pigmentation (CR), 1316reported adverse effects of isotretinoin and
systemic corticosteroids (RR), 287short-term and low-dose oral fluconazole
treatment can cause Stevens-Johnson syndrome in HIV-negative patients (letter to the editor), 1360
sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features (CR), 308
tamoxifen-induced hirsutism (CR), 799Drug resistance
antibiotic resistance: an editorial review with recommendations, 724
FDA approves Ceftaroline for MRSA (PP), 104recent advances and future directions in
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
medical management of skin disease, 28
Dutasteridein female androgenetic alopecia (NVR), 98versus placebo and finasteride in men with
androgenetic alopecia (CTR), 936Dyschromia, laser treatment with novel 607 nm
pulsed-dye laser, 388
EEastern Virginia Medical School Residency
Programprogram spotlight on (RR), 344ticks of dermatologic significance (RR), 365viral-associated trichodysplasia of
immunosuppression in renal transplant patient (RR), 422
Editorialscancer: this war is personal, 237commentary on rheological evaluation of the
physical properties of hyaluronic acid dermal fillers, 964
cosmetic treatments on skin of color, a unique challenge, s4 (December)
defining the future of dermatology, 15doxycycline versus minocycline for
management of acne, 965, 966introduction to demystifying acne algorithms
supplement, s7 (June)introduction to DermPearls supplement, s4
(December)JDD goes international, 581JDD receives impact factor ranking of 1.954,
1234lessons from an exemplary physician in
private setting, 238new face of fillers: why evidence and
experience both count, 964role of stratum corneum in healthy and
diseased skin, s4 (October)short-term and low-dose oral fluconazole
treatment can cause Stevens-Johnson syndrome in HIV-negative patients, 1360
skin of color: progress made, challenges remain, 459
ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream, 240
why are dermatologists still talking about acne? because so many people have it, and we are always seeking better ways to manage it, 575
Efalizumab, diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis (CR), 80
Elastography, ultrasonic, in skin neoplasms (CTR), 319
Electrocardiography, isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
Electronic medical records, creation of electronic drug calendar in drug hypersensitivity, 1430
Eletone cream, bilateral comparison study of pimecrolimus cream 1% and medical device cream in atopic dermatitis, 735
Epidermolysis bullosa simplex with mottled pigmentation, novel KRT14 mutation in (CR), 926
Erbium:YAG micropeel treatment, prospective randomized trial on effects of fluence
settings for facial photoaging, 179Erlotinib, phase 2 trial in squamous cell cancer
prior to surgery or radiation (CTR), 207Erythema
erythema multiforme-like drug reaction to sorafenib (CR), 1462
fulminant dermatomyositis with flagellate erythema (RR), 902
phase 3 efficacy and study of CD07805/47 topical gel in facial erythema associated with rosacea (CTR), 1216
thalidomide and complement activation in erythema nodosum leprosum, 274
Erythrasma, case of trichomycosis axillaris and (RR), 1472
Erythromycin in fixed-combination therapy for acne, compared to retinoid monotherapy, 636
Estrogen, advantages of oral contraceptives and spironolactone for women with acne (DP), 941
Etanerceptclinical trial safety and mortality analysis
across approved indications, 289open-label prospective cohort pilot study on
efficacy and safety in moderate to severe plaque psoriasis in patients without adequate response to adalimumab, 396
retrospective study of racial and ethnic variations in psoriasis treatment with, 866
safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis (CTR), 1216
as sole treatment for grade I acute graft versus host disease (CTR), 1487
topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in moderate-to-severe plaque psoriasis, 878
Ethnicity. See Race/ethnicityEtretinate, depression associated with, 409Extensiometry, evaluation of moisturizing effect
of methanolic extract of five medicinal plants incorporated into cream bases using, 1116
Eyelid, modified Tripier flap for lateral eyelid reconstruction (CR), 199
FFacial lipoatrophy, evolution of injectable poly-L-
lactic acid from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001
Facial rejuvenationclinical evidence for activity of
tetrahydroxypropyl ethylenediamine (THPE) as new anti-aging active cosmetic, 1102
combined treatment for skin rejuvenation and soft-tissue augmentation of aging face, 125
Ellman International introduces Pellevé Wrinkle Reduction System to European market (PP), 938
evolution of injectable poly-L-lactic acid from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001
FDA approval for Syneron LED-based skin
rejuvenation system (PP), 435guide to temporal fossa augmentation with
small gel particle hyaluronic acid dermal filler, 673
histological and immunohistochemical evaluation of intense pulsed light photorejuvenation, 1246
multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352
safety and efficacy of cosmetic laser treatments for skin of color, 36
tower technique for injection of hyaluronic acid fillers in, 1277
Feverfewaesthetic benefits of natural ingredients in
skin care, s12 (September)in atopic dermatitis and other inflammatory
skin diseases, s6 (September)Fibroblasts
complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts, 753
green tea extract protects human skin fibroblasts from reactive oxygen species induced necrosis, 1096
Fibrosis, nephrogenic systemicalefacept therapy for (CR), 922case report and literature review (RR), 622
Finasteridedutasteride versus placebo and finasteride
in men with androgenetic alopecia (CTR), 936
in female androgenetic alopecia (NVR), 98Fitzpatrick skin types
acne in patients with skin of color, s13 (June)fractional laser resurfacing for acne scarring
in Fitzpatrick skin types IV–VI (DP), s6 (December)
safety and efficacy of cosmetic laser treatments for skin of color, 35
ten tips for acne vulgaris treatment in Fitzpatrick skin types IV–VI (BC), 654
Fixed drug eruption associated with iohexol intravenous contrast media (CR), 802
Fluconazole, short-term and low-dose oral fluconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients (letter to the editor), 1360
Fluocinonideeffects of novel formulation on skin barrier
function in atopic dermatitis, 171efficacy of fluocinonide cream 0.1% in
reducing itch in atopic dermatitis (CTR), 1486
5-Fluorouracilmetallic taste as side effect of (CR), 1201optimal use in keloids (NVR), 548prospective case-based assessment of
sequential therapy with topical fluorouracil cream and ALA-PDT for actinic keratosis, 372
Fluticasone propionate, injection lipolysis of abdominal subcutaneous fat yields results (PP), 103
Follistatin, hair regrowth following a Wnt- and follistatin-containing treatment, safety and efficacy in first-in-man phase 1 clinical trials, 1308
Food and Drug AdministrationAbbott withdraws briakinumab from FDA
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
review (PP), 435approval of Allergan cell-based assay for
BOTOX (PP), 938approval of Benlysta for lupus erythematosus
(PP), 806approval of Botox for chronic migraine (PP),
104approval of Ceftaroline for MRSA (PP), 104approval of Fibrocell Science LAVIV (PP), 939approval of first generic versions of
levofloxacin (PP), 1076approval of Gardasil to prevent anal cancer
(PP), 325approval of Glenmark Generics mupirocin 2%
ointment (PP), 939approval of imiquimod 5% cream (PP), 683approval of ipilimumab (PP), 552approval of Natroba for head lice (PP), 434approval of Rectiv (nitroglycerin) ointment
(PP), 939approval of Rituxan with corticosteroids for
severe vasculitis (PP), 683approval of Sorilux (calcipotriene) foam (PP),
103approval of Sylatron to treat melanoma (PP),
684approval of Syneron LED-based skin
rejuvenation system (PP), 435approval of Xeomin (incobotulinumtoxinA)
(PP), 1076approval of Zelboraf (vemurafenib) (PP), 1215approval of Zyclara Cream 3.75% for external
genital warts (PP), 552ban on skin whitening products containing
mercury (PP), 1215Cardium Therapeutics announces FDA 510(k)
clearance for Excellagen (PP), 1478clearance of EndyMed Fractional Skin
Resurfacing Applicator (PP), 435clearance of PinPointe FootLaser for nail
fungus (PP), 104Cleure launches FDA-approved broad-
spectrum sunscreen (PP), 1076Fibrocell Science, Inc. and azficel-T (PP), 325Genentech submits New Drug Application to
(PP), 1340Graceway receives FDA approval for Zyclara
Cream 2.5% for actinic keratosis (PP), 1076
grants marketing clearance for HairMax Dual 12 home-use laser phototherapy device (PP), 1341
Helix Biopharma Corp. files clinical hold response on topical interferon alpha-2b (PP), 1478
New Drug Application for Yaupon’s mechlorethamine hydrochloride (PP), 1478
new drug applications for vemurafenib in advanced skin cancer (PP), 805
panel votes in favor of MelaFind skin cancer detection device (PP), 213
provisional approval to MelaFind device (PP), 1340
Sagent Pharmaceuticals announces FDA approval of bupivacaine hydrochloride injection (PP), 1478
warning letter to Jaba Labs LLC (PP), 552Foot
clinical evaluation of safety and efficacy of new topical treatment for onychomycosis, 1186
dermaPACE device for diabetic foot ulcers (PP), 325
once-daily therapy with sertaconazole nitrate for interdigital tinea pedis, 1135
randomized double-blind vehicle-controlled efficacy and safety study of naftifine 2% cream in tinea pedis, 1282
Fractionated laser therapyfor acne scarring in Fitzpatrick skin types IV–VI
(DP), s6 (December)Alma Lasers introduces iPixel fractional
ablative technology (PP), 805burn scar appearance after fractional carbon
dioxide laser treatment (CTR), 96evaluation of clinical improvement in acne
scars and active acne in 1540-nm non-ablative fractional laser treatment, 907
multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352
multiplexed 1,440 and 1,320 nm fractionated laser for chronic photodamage, 1266
nonablative 1927 nm fractional resurfacing for actinic keratoses (PP), 103
Frontalis Activity Measurement Standardcomparing clinical attributes of
abobotulinumtoxinA and onabotulinumtoxinA using, 1148
novel contralateral method for assessing botulinum neurotoxin type-A activity, 968
Frontalis Rating Scaleassessing botulinum neurotoxin type-A
activity with, 968comparing clinical attributes of
abobotulinumtoxinA and onabotulinumtoxinA using, 1148
Fungal infectionsclinical evaluation of safety and efficacy
of new topical treatment for onychomycosis, 1186
double-blind randomized vehicle-controlled study on efficacy and safety of naftifine 2% cream in tinea cruris, 1142
once-daily therapy with sertaconazole nitrate for interdigital tinea pedis, 1135
randomized double-blind vehicle-controlled efficacy and safety study of naftifine 2% cream in tinea pedis, 1282
role of lasers in onychomycosis (NVR), 1074short-term and low-dose oral fluconazole
treatment can cause Stevens-Johnson syndrome in HIV-negative patients (letter to the editor), 1360
GGabapentin, post-herpetic itch resolved with (CR),
85Gadolinium, alefacept therapy for nephrogenic
systemic fibrosis associated with (CR), 922
Gardasil, FDA approval for prevention of anal cancer (PP), 325
GDC-0449, study on efficacy and safety in operable basal cell carcinoma (CTR), 206
Gelatin sponges in Mohs micrographic surgery defects and staged melanoma excisions, 68
Gemcitabine and pemetrexed disodium in advanced mycosis fungoides or Sézary syndrome (CTR), 210
Geneticsgenes in psoriasis (NVR), 1337recent advances and future directions in
medical management of skin disease, 28
Genital warts, external, FDA approves Zyclara Cream 3.75% for (PP), 552
Glabellar linescomparing clinical attributes of
abobotulinumtoxinA and onabotulinumtoxinA using Frontalis Rating Scale and Frontalis Activity Measurement Standard, 1148
corrugator supercilii muscle terminal nerve ablation using novel thread technique for treatment of hyperdynamic vertical glabellar furrows, 762
FDA approval of Xeomin (incobotulinumtoxinA) for (PP), 1076
rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines, 39
Glycolic acidcomparison of 1% tretinoin peeling versus
70% glycolic acid peeling in female patients with melasma, 1439
in Gly-Sal Acne Body Spray (PP), 434Glycyrrhetinic acid-containing barrier repair
cream (BRC-Gly), compared to OTC moisturizer for mild-to-moderate atopic dermatitis in children, 531
Graft versus host disease, acute grade I, use of etanercept as sole treatment for (CTR), 1487
Granuloma annulare, recalcitrant, treatment with adalimumab (CR), 1466
Graves disease, iododerma following radioactive iodine ablation of thyroid for (RR), 1070
Green teaaesthetic benefits of natural ingredients in
skin care, s12 (September)complementary antioxidant function of
caffeine and green tea polyphenols in normal human skin fibroblasts, 753
green tea extract protects human skin fibroblasts from reactive oxygen species induced necrosis, 1096
Growth factors, decrease of insulin growth factor-1 as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793
HHair
advances in laser hair removal in skin of color, 1235
approvals, long-term safety data, cancer risk, and treatment options in androgenetic alopecia in women (NVR), 98
case of trichomycosis axillaris and erythrasma (RR), 1472
comparison of high-fluence single-pass diode laser to low-fluence multiple-pass diode laser for hair reduction with 18 months of follow up, 62
comparison of sequential treatment with diode and alexandrite lasers versus alexandrite laser alone in hirsutism, 1255
dutasteride versus placebo and finasteride
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
in men with androgenetic alopecia (CTR), 936
FDA grants marketing clearance for HairMax Dual 12 home-use laser phototherapy device (PP), 1341
hair findings board review (RR), 1464hair regrowth following a Wnt- and follistatin-
containing treatment, safety and efficacy in first-in-man phase 1 clinical trials, 1308
laser hair removal in ethnic skin, principles and practical aspects of (DP), s17 (December)
laser hair removal pearls in skin of color (DP), s12 (December)
novel 0.65 millisecond pulsed 1064 nm laser to treat skin of color without skin cooling or anesthetics (DP), s10 (December)
novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution (CR), 795
randomized double-blind placebo-controlled clinical trial on efficacy of abatacept costimulatory blockade in alopecia totalis/universalis, 1342
ROGAINE introduces Unscented Topical Foam (PP), 1076
role of inflammation and immunity in pathogenesis of androgenetic alopecia, 1404
safety and efficacy of clobetasol propionate 0.05% emollient foam in alopecia (CTR), 1077
safety and efficacy of laser hair removal for skin of color, 35
safety and efficacy study of bimatoprost in women with female pattern hair loss (CTR), 936
scalp hyperkeratosis and alopecia in children of color, 511
START (Swiss Taxotere Alopecia Prevention Trial) (CTR), 936
tamoxifen-induced hirsutism (CR), 799Hand
open-label study on treatment of mild-to-moderate chronic hand dermatitis with clobetasol propionate 0.05% emulsion formulation foam, 1398
safety and efficacy of calcium hydroxylapatite for rejuvenation of aging hand, 47
Harvard Combined Dermatology Residency Training Program
high-yield dermatologic signs in (RR), 197program spotlight on (RR), 186
Head and neck cancerMohs micrographic surgery for cutaneous
lymphadenoma (CR), 1324review of chemopreventative effects of oral
retinoids for, 1292Head lice, FDA approves Natroba for (PP), 434Health care costs
increased prevalence of psychiatric disorders and health care-associated costs in moderate-to-severe psoriasis, 843
medication choice and associated health care outcomes and costs in acne and acne-related conditions, 766
Health care outcomes, medication choice and associated health care outcomes and costs in acne and acne-related conditions, 766
Heart
isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900
psoriasis drugs not linked to increased heart risks (PP), 1215
Hemodialysis, randomized-withdrawal phase 3 study on safety and efficacy of nalfurafine HCl (AC-820) for uremic pruritus in (CTR), 91
Hepatocellular carcinomaclinical clues and patterns in biopsy diagnosis
of cutaneous metastases of (NVR), 678, 930
review of chemopreventative effects of oral retinoids for, 1292
sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in (CR), 308
Herbal extractsevaluation of moisturizing effect of
methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensiometry methods, 1116
randomized double-blind petrolatum-controlled study on efficacy of oregano extract ointment in wound healing, 1168
Herpes simplex labialis, randomized double-blind placebo-controlled multi-center trial of zinc for (CTR), 1343
Herpes zosterbullous pemphigoid after herpes zoster
vaccine administration (CR), 1328herpes zoster vaccine reduces zoster risk (PP),
324post-herpetic itch resolved with gabapentin
(CR), 85Hidradenitis suppurativa, preliminary results of
treatment with ALA-PDT, 381Hirsutism
comparison of sequential treatment with diode and alexandrite lasers versus alexandrite laser alone in, 1255
safety and efficacy of laser hair removal in, 35tamoxifen-induced (CR), 799
Histiocytosis, intralymphatic, associated with orthopedic implants (RR), 1208
Histology, histological and immunohistochemical evaluation of intense pulsed light photorejuvenation, 1246
HIV infection and AIDSerosive and desquamative syphilis associated
with mucositis in setting of AIDS (RR), 1335
evolution of injectable poly-L-lactic acid from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001
lenalidomide in AIDS-related Kaposi sarcoma (CTR), 210
liposomal daunorubicin in HIV-related Kaposi’s sarcoma (CTR), 212
PTC299 in HIV-related Kaposi sarcoma (CTR), 211
syphilis and lues maligna in, a noduloulcerative disease that still lingers after all these centuries (RR),
1072Hormonal therapy, advantages of oral
contraceptives and spironolactone for women with acne (DP), 941
Hyaluronic acid (HA)bilateral comparison study of pimecrolimus
cream 1% and ceramide-HA emollient foam in atopic dermatitis, 666
commentary on rheological evaluation of the physical properties of HA dermal fillers (letter to the editor), 964
efficacy and tolerability of new monophasic double-crosslinked HA filler for deep lines and wrinkles, 134
efficacy of cream-based novel formulations of HA of different molecular weights in anti-wrinkle treatment, 990
guide to temporal fossa augmentation with small gel particle HA dermal filler, 673
management of impending necrosis associated with soft tissue filler injections (CR), 1007
new face of fillers: why evidence and experience both count (letter to the editor), 964
open-label pilot study on effectiveness and safety in lip augmentation, 145
Restylane for lip augmentation (PP), 684rheological evaluation of physical properties
of HA dermal fillers, 974safety and effectiveness of small and large
gel-particle HA in correction of perioral wrinkles, 982
solid HA tailored to fix fine wrinkles (PP), 1341tower technique for injection of, 1277
Hydrogels, polyacrylamide, characteristics of different products, 1370
Hydroquinone, evaluation of prescription strength 4% hydroquinone/10% L-ascorbic acid treatment system for photodamage in normal to oily skin, 1455
Hyperdynamic vertical glabellar furrows, corrugator supercilii muscle terminal nerve ablation using novel thread technique for treatment of, 762
Hyperhidrosis, axillary, same-patient prospective comparison and literature review of Botox versus Dysport for (CR), 1013
Hyperkeratosis of scalp and alopecia in children of color, 511
HyperpigmentationLa Roche-Posay introduces new products
(PP), 938natural therapies for, s11 (September), s15
(September)in nephrogenic systemic fibrosis, case report
and literature review on (RR), 622post-inflammatory, and acne in patients with
skin of color, s13 (June)post-inflammatory, efficacy and safety of
azelaic acid gel 15% in acne and, 586
post-inflammatory, strategies minimizing, in treatment of acne patients with skin of color (DP), s25 (December)
Q-switched laser treatment of amiodarone pigmentation (CR), 1316
Hypersensitivity reactions during selective serotonin reuptake inhibitor therapy resulting in acquired cutis laxa (RR), 215
Hypomelanosis, progressive macular, 502
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
IIbuprofen, cutaneous reactions to non-steroidal
anti-inflammatory drugs, 1160IDP-107, dose-ranging study on safety and efficacy
in acne vulgaris (CTR), 426Imatinib
in mucosal or acral/lentiginous melanoma (CTR), 208
pigmentary changes in patient treatment with (CR), 1062
Imiquimodin combination with cryotherapy in treatment
of hypertrophic actinic keratosis (CTR), 426
compared to cryotherapy in actinic keratoses, lesion clearance, safety, and skin quality outcomes in, 1432
FDA approves Zyclara Cream 3.75% for external genital warts (PP), 552
Graceway receives FDA approval for Zyclara Cream 2.5% for actinic keratosis (PP), 1076
long-term sustained complete clearance of actinic keratoses of face or balding scalp after treatment with, 165
with Nd:YAG laser for tattoo removal (CTR), 1342
optimal use in keloids (NVR), 548regression of internal melanoma metastases
after topical application of (CR), 302review of off-label clinical applications, 1300Taro receives FDA approval for imiquimod 5%
cream (PP), 683treatment of actinic keratosis of face with
imiquimod cream followed by photodynamic therapy (CTR), 426
ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream (letter to the editor), 240
Immune functionautoimmune-mediated blisters (RR), 491CD70 and Th17 involvement in human contact
sensitivity (BC), 1192fatal cutaneous strongyloidiasis as side
effect of mycophenolate mofetil in pemphigus foliaceus in immunocompromised patient (CR), 418
inflammation in rosacea and acne, and implications for patient care, 586
role of inflammation and immunity in pathogenesis of androgenetic alopecia, 1404
T cell repertoire analysis of immune mediated skin diseases (CTR), 936
Immunoglobulin, intravenous, with or without cyclophosphamide in pemphigus (CTR), 1077
Immunosuppressioncase report of pyoderma gangrenosum
following breast reconstructive surgery treated with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545
viral-associated trichodysplasia of, in renal transplant patient (RR), 422
Impact Factor Ranking of JDD (editorial), 1234Impedance measurements, evaluation of
moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using, 1116
IncobotulinumtoxinAFDA approval for glabellar lines (PP), 1076
treatment of notalgia paresthetica with (CTR), 91
Inflammationefficacy and safety of azelaic acid gel
15% in post-inflammatory hyperpigmentation and acne, 586
post-inflammatory hyperpigmentation and acne in patients with skin of color, s13 (June)
role of inflammation and immunity in pathogenesis of androgenetic alopecia, 1404
in rosacea and acne, implications for patient care, 614
strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)
Infliximab, review of psoriasis treatment in 120 patients on therapy for a minimum of one year, 539
Insulin growth factor-1, decrease of IGF-1 as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793
Intense pulsed light photorejuvenation, histological and immunohistochemical evaluation of, 1246
Interferonefficacy of vorinostat in combination with
interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sézary syndrome (BC), 403
FDA approves Sylatron to treat melanoma (PP), 684
Helix Biopharma Corp. files clinical hold response on topical interferon alpha-2b (PP), 1478
taurine chloramine inhibits NO and TNF-a production in zymosan plus interferon-g activated RAW 264.7 cells, 659
International alliance of JDD (editorial), 581Intravenous immunoglobulin with or without
cyclophosphamide in pemphigus (CTR), 1077
Iododerma following radioactive iodine ablation of thyroid for Graves disease (RR), 1070
Iohexol, fixed drug eruption associated with intravenous contrast media (CR), 802
Ipilimumab, FDA approval of (PP), 552Irritation of skin from treatment
patient experience and management of dryness and irritation from acne treatment, 605
safety and efficacy of micronized tretinoin 0.05% gel in adolescent acne, 647
strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)
in topical rosacea therapy, vehicle formulations affecting, 627
Isotretinoindecrease of insulin growth factor-1 as novel
mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793
depression associated with, 409isotretinoin does not prolong QT intervals
and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
reported adverse effects of systemic corticosteroids and (RR), 287
JJournal of Drugs in Dermatology
international alliance of (editorial), 581receives impact factor ranking of 1.954
(editorial), 1234
KKaposi sarcoma, AIDS and HIV-related
lenalidomide in (CTR), 210liposomal daunorubicin in (CTR), 212PTC299 in (CTR), 211
Keloidsadvances in treatment of, 468new treatments in (NVR), 548
Keratinocytesclinical evidence for activity of
tetrahydroxypropyl ethylenediamine (THPE) as new anti-aging active cosmetic, 1102
treatment of vitiligo with melanocyte-keratinocyte cell suspension versus dermabrasion only in pilot study with 12-month follow-up, 1032
Keratoacanthoma, eruptive squamous cell carcinomas with keratoacanthoma-like features in patients treated with sorafenib (CR), 308
Kidneysalefacept therapy for nephrogenic systemic
fibrosis (CR), 922chloracne-like drug eruption associated with
sorafenib in metastatic renal cell carcinoma (CR), 1331
clinical clues and patterns in biopsy diagnosis of cutaneous metastases of renal carcinoma (NVR), 678, 930
is chronic cutaneous discoid lupus protective against severe renal disease in systemic lupus erythematosus?, 1413
melanoma in renal transplant patient (RR), 808
nephrogenic systemic fibrosis case report and literature review (RR), 622
randomized-withdrawal phase 3 study on safety and efficacy of nalfurafine HCl (AC-820) for uremic pruritus in renal disease (CTR), 91
viral-associated trichodysplasia of immunosuppression in renal transplant patient (RR), 422
Koebner phenomenon, tattoo sites and psoriasis (CR), 1199
Kojic acid in natural therapies for hyperpigmentation, s17 (September)
KRT14 mutation in epidermolysis bullosa simplex with mottled pigmentation (CR), 926
LLanthanum carbonate, evaluation of efficacy in
calciphylaxis (CTR), 1342Laser technology
advances in laser hair removal in skin of color, 1235
Alma Lasers introduces iPixel fractional ablative technology (PP), 805
best practices and evidence-based use of 800 nm diode laser for pseudofolliculitis barbae in skin of color (DP), s20
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
(December)burn scar appearance after fractional carbon
dioxide laser treatment (CTR), 96in combined treatment for skin rejuvenation
and soft-tissue augmentation of aging face, 125
comparison of high-fluence single-pass diode laser to low-fluence multiple-pass diode laser for hair reduction with 18 months of follow up, 62
comparison of sequential treatment with diode and alexandrite lasers versus alexandrite laser alone in hirsutism, 1255
confocal scanning laser microscopy, 21diode 810 nm laser as safe, effective modality
to meet a growing population need (DP), s8 (December)
effects of pulsed-dyed laser on scar formation (CTR), 96
evaluation of clinical improvement in acne scars and active acne in 1540-nm non-ablative fractional laser treatment, 907
FDA clearance of PinPointe FootLaser for nail fungus (PP), 104
FDA grants marketing clearance for HairMax Dual 12 home-use laser phototherapy device (PP), 1341
fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI (DP), s6 (December)
laser hair removal in ethnic skin, principles and practical aspects of (DP), s17 (December)
laser hair removal pearls in skin of color (DP), s12 (December)
multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352
multiplexed 1,440 and 1,320 nm fractionated laser for chronic photodamage, 1266
nonablative 1927 nm fractional resurfacing for actinic keratoses (PP), 103
novel 0.65 millisecond pulsed 1064 nm laser to treat skin of color without skin cooling or anesthetics (DP), s10 (December)
promising future of laser and light therapy, 32prospective randomized trial on effects of
fluence settings in Er:YAG micropeel for facial photoaging, 179
Q-switched laser treatment of amiodarone pigmentation (CR), 1316
role in onychomycosis (NVR), 1074safety and efficacy of cosmetic laser
treatments for skin of color, 35safety of tumescent and laser-assisted
liposuction, review of literature on, 1363
topical imiquimod with Nd:YAG laser for tattoo removal (CTR), 1342
treating lentigines in Asian patients with Q-switched Alexandrite laser (DP), s14 (December)
treatment of dyschromia with novel 607 nm pulsed-dye laser, 388
treatment of surgical scars using pulsed dye laser (CTR), 96, 1216
XTRAC laser for psoriasis (PP), 938Latin Americans, melasma in, 517Lenalidomide
in AIDS-related Kaposi sarcoma (CTR), 210in relapsed mycosis fungoides/Sézary
syndrome (CTR), 209Lentigines, treating lentigines in Asian patients
with Q-switched Alexandrite laser (DP), s14 (December)
Letters to the editorcommentary on rheological evaluation of the
physical properties of hyaluronic acid dermal fillers, 964
doxycycline versus minocycline for management of acne, 965, 966
new face of fillers: why evidence and experience both count, 964
short-term and low-dose oral fluconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients, 1360
ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream, 240
Leukemiaclinical clues and patterns in biopsy diagnosis
of cutaneous metastases of (NVR), 678, 930
dasatinib in unresectable or metastatic squamous cell skin cancer or RAI stage 0-1 chronic lymphocytic leukemia (CTR), 207
Levamisolelevamisole induced necrosis of skin and
neutropenia following intranasal cocaine use: a newly recognized syndrome (CR), 1204
retiform purpura from (RR), 217Levocetirizine, and rupatadine in chronic
idiopathic urticaria, comparative study of efficacy and safety, 1444
Levofloxacin, FDA approves first generic versions of (PP), 1076
Lice, FDA approves Natroba for head lice (PP), 434Lichen planus following Tdap vaccination (CR),
1067Licorice
aesthetic benefits of natural ingredients in skin care, s12 (September)
in atopic dermatitis and other inflammatory skin diseases, s6 (September)
evaluation of moisturizing effect of methanolic extract incorporated into cream bases using impedance and extensiometry methods, 1116
in natural therapies for hyperpigmentation, s17 (September)
Light emitting diode (LED) systemsFDA approval of Syneron LED-based skin
rejuvenation system (PP), 435self-treatment of mild-to-moderate facial acne
with blue light treatment system, 596
Taenda Luxe device for home treatment of periorbital wrinkles (PP), 1215
Light therapy. See PhototherapyLip
open-label pilot study on effectiveness and safety of hyaluronic acid in lip augmentation, 145
randomized double-blind placebo-controlled multi-center trial of zinc for herpes simplex labialis (CTR), 1343
Restylane for lip augmentation (PP), 684treatment of actinic cheilitis by photodynamic
therapy with 5-aminolevulinic acid and blue light activation, 1240
Lipoatrophy, facial, evolution of injectable poly-L-lactic acid from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001
Lipolysis, injection lipolysis of abdominal subcutaneous fat yields results (PP), 103
Liposuction, safety of tumescent and laser-assisted liposuction, review of literature on, 1363
Liver cancerclinical clues and patterns in biopsy diagnosis
of cutaneous metastases of (NVR), 678, 930
review of chemopreventative effects of oral retinoids for, 1292
sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in (CR), 308
Lues malignaerosive and desquamative syphilis associated
with mucositis in setting of AIDS (RR), 1335
a noduloulcerative disease that still lingers after all these centuries (RR), 1072
Lung cancer, clinical clues and patterns in biopsy diagnosis of cutaneous metastases (NVR), 678, 930
Lupus erythematosusFDA approves Benlysta for (PP), 806is chronic cutaneous discoid lupus protective
against severe renal disease in systemic lupus erythematosus?, 1413
manifestations and treatment of (NVR), 1212, 1474
LY2439821 in moderate-to-severe psoriasis (CTR), 94
Lymph nodes, comparison of elective lymph node treatment versus clinical observation in absence of palpable lymph nodes in high risk squamous cell carcinoma (CTR), 207
Lymphadenoma, cutaneous, Mohs micrographic surgery for (CR), 1324
Lymphomaclinical clues and patterns in biopsy diagnosis
of cutaneous metastases of (NVR), 678, 930
diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis (CR), 80
Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PROPEL) (PP), 213
review of chemopreventative effects of oral retinoids for cutaneous T cell lymphoma, 1292
study evaluating two dose levels of Targretin capsules in refractory cutaneous T-cell lymphoma (CTR), 209
MMallow, evaluation of moisturizing effect of
methanolic extract incorporated into cream bases using impedance and extensiometry methods, 1116
Marsh horsetail, evaluation of moisturizing effect of methanolic extract incorporated into cream bases using impedance and extensiometry methods, 1116
Matrix scaffolds, xenogeneic, case report of pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and (RR), 545
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
Mechlorethamine hydrochloride, New Drug Application for (PP), 1478
Medication choice, and associated health care outcomes and costs in acne and acne-related conditions, 766
Medicinal plantscomparative study of safety and efficacy of
75% mulberry extract oil versus placebo as topical treatment for melasma, 1025
evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensiometry methods, 1116
randomized double-blind petrolatum-controlled study on efficacy of oregano extract ointment in wound healing, 1168
MelaFind skin cancer detection devicecomparison of diagnostic and biopsy/referral
sensitivity to melanoma between dermatologists and MelaFind (RS), 1078
FDA gives provisional approval to (PP), 1340FDA panel votes in favor of (PP), 213
Melanin synthesis, s16 (September)Melanocytes, treatment of vitiligo with
melanocyte-keratinocyte cell suspension versus dermabrasion only in pilot study with 12-month follow-up, 1032
Melanomaclinical clues and patterns in biopsy diagnosis
of cutaneous metastases (NVR), 678, 930
comparison of diagnostic and biopsy/referral sensitivity to melanoma between dermatologists and MelaFind (RS), 1078
dasatinib in locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery (CTR), 208
detection by oblique-incidence optical spectroscopy (CTR), 318
early detection and cure in serial screening program, 244
FDA approves Sylatron to treat (PP), 684FDA gives provisional approval to MelaFind
device (PP), 1340FDA panel votes in favor of MelaFind skin
cancer detection device (PP), 213imatinib in mucosal or acral/lentiginous
melanoma (CTR), 208lessons from an exemplary physician in
private setting (editorial), 238new drug applications for vemurafenib in
advanced skin cancer (PP), 805positive results in PLX4032 study (PP), 103regression of internal melanoma metastases
after topical application of imiquimod (CR), 302
in renal transplant patient (RR), 808as second cancer (NVR), 320second cancers after (NVR), 320sorafenib and temsirolimus in metastatic,
recurrent, or unresectable melanoma (CTR), 207
study confirms sunscreen prevents (PP), 213trends in treatment and detection of skin
cancer, 16use of gelatin sponges in Mohs micrographic
surgery and staged melanoma excision, 68
Melanosome transfer, s16 (September)Melasma
comparative study of safety and efficacy of 75% mulberry extract oil versus placebo as topical treatment for, 1025
comparison of 1% tretinoin peeling versus 70% glycolic acid peeling in female patients with, 1439
in Latin Americans, 517pilot study using reflectance confocal
microscopy in assessment of novel formulation for, 1260
Mercury, FDA bans skin whitening products containing (PP), 1215
Merkel cell carcinoma, as banal-appearing aggressive actor (NVR), 811
Metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900
Metallic taste as side effect of topical fluorouracil, 1201
Metastasesbiopsy diagnosis: clinical clues and patterns
to help distinguish cutaneous metastases (NVR), 678, 930
dasatinib in unresectable or metastatic squamous cell skin cancer or RAI stage 0-1 chronic lymphocytic leukemia (CTR), 207
regression of internal melanoma metastases after topical application of imiquimod (CR), 302
Methanolic extract, evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensiometry methods, 1116
Methemoglobinemia risk from benzocaine topical products (PP), 684
Methicillin-resistant Staphylococcus aureus, FDA approves Ceftaroline for (PP), 104
Methyl aminolevulinate (MAL), safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
Metronidazolein novel rosacea treatment system,
investigator-blind randomized parallel-group study on, 1179
in topical rosacea therapy, vehicle formulations for, 627
Micro-dosing system, CoreRx Pharmaceuticals introduces Xcelodose micro-dosing system (PP), 1478
Migraine, chronic, FDA approves Botox for (PP), 104
Minocyclinein combination treatment for moderate-to-
severe acne (CTR), 90compared to doxycycline for management of
acne (letter to the editor), 965, 966Minoxidil, ROGAINE introduces Unscented Topical
Foam (PP), 1076Mohs micrographic surgery
for cutaneous lymphadenoma (CR), 1324three-dimensional technique as new concept,
1273triage in, 257use of gelatin sponges in, and secondary
wound healing, 68Moisturizers
evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensiometry methods, 1116
new body moisturizer increases skin hydration and improves AD symptoms in children and adults, 714
in novel rosacea treatment system, investigator-blind randomized parallel-group study on, 1179
over-the-counter moisturizer compared to prescription barrier creams in mild-to-moderate atopic dermatitis of children, 531
Monoclonal antibodies, study of human monoclonal antibody (zanolimumab) to treat mycosis fungoides and Sézary syndrome (CTR), 1077
Muckle-Wells syndrome, severe, anakinra effective for (PP), 214
Mucositis, erosive, and desquamative syphilis, in setting of AIDS (RR), 1335
Mulberry aesthetic benefits of natural ingredients in
skin care, s11 (September)comparative study of safety and efficacy of
75% mulberry extract oil versus placebo as topical treatment for melasma, 1025
Mupirocin, FDA approval of Glenmark Generics mupirocin 2% ointment (PP), 939
Mycobacterial infectionMycobacterium fortuitum infection following
adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-a blockers (CR), 914
thalidomide and complement activation by M. leprae, 274
Mycophenolate mofetil in pemphigus foliaceus, fatal cutaneous strongyloidiasis as side effect of (CR), 418
Mycosis fungoides/Sézary syndromeefficacy of vorinostat in combination with
interferon alpha and extracorporeal photopheresis in late stage of (BC), 403
gemcitabine and pemetrexed disodium in advanced stage of (CTR), 210
lenalidomide in relapse of (CTR), 209new analysis demonstrates activity in
relapsed or refractory transformed mycosis fungoides (PP), 213
study of human monoclonal antibody (zanolimumab) in (CTR), 1077
study of total skin electron beam therapy in stage IB-IIIA mycosis fungoides (CTR), 209
T cell repertoire analysis of immune mediated skin diseases (CTR), 936
NNaftifine 2% cream
double-blind randomized vehicle-controlled study on efficacy and safety in tinea cruris, 1142
double-blind randomized vehicle-controlled study on efficacy and safety in tinea pedis, 1282
Nail disorders
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
clinical evaluation of safety and efficacy of new topical treatment for onychomycosis, 1186
FDA clearance of PinPointe FootLaser for onychomycosis (PP), 104
role of lasers in onychomycosis (NVR), 1074Nalfurafine HCl (AC-820), randomized-withdrawal
phase 3 study on safety and efficacy in hemodialysis and uremic pruritus (CTR), 91
Nalmefene, efficacy, safety, and tolerability of SRD174 cream for pruritus in atopic dermatitis, 853
Nanotechnology, and dermatology education in United States, data from pilot survey, 1037
Nasal basal cell carcinoma, ulcerated nodular, successfully treated with imiquimod 5% cream (letter to the editor), 240
Nasolabial folds and wrinkles, azficel-T in (PP), 325
Natural ingredientsaesthetic benefits of, s10 (September)in atopic dermatitis and other inflammatory
skin diseases, s6 (September)CME: identifying natural ingredients and their
use in skin care, s4 (September), s21 (September), s22 (September)
comparative study of safety and efficacy of 75% mulberry extract oil versus placebo as topical treatment for melasma, 1025
cosmeceutical and nutraceutical horizons, 24defining terms in, s10 (September)evaluation of moisturizing effect of
methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensiometry methods, 1116
in hyperpigmentation, s11 (September), s15 (September)
randomized double-blind petrolatum-controlled study on efficacy of oregano extract ointment in wound healing, 1168
Stiefel/GSK introduces Illumuminesse Brightening Complex (PP), 938
Nd:YAG laser and topical imiquimod for tattoo removal (CTR), 1342
Necrosisgreen tea extract protects human skin
fibroblasts from reactive oxygen species induced necrosis, 1096
levamisole induced necrosis of skin and neutropenia following intranasal cocaine use: a newly recognized syndrome (CR), 1204
management of impending necrosis associated with soft tissue filler injections (CR), 1007
Neodymium:YAG laser and topical imiquimod for tattoo removal (CTR), 1342Neonates, phototherapy-induced purpura in
transient porphyrinemia of (RR), 306Neoplasia
biopsy diagnosis: clinical clues and patterns to help distinguish cutaneous metastases (NVR), 678, 930
cancer: this war is personal (editorial), 237clinical trial of Dermacorder for detecting
malignant skin lesions (CTR), 317comparison of diagnostic and biopsy/referral
sensitivity to melanoma between dermatologists and MelaFind (RS),
1078comparison of elective lymph node treatment
versus clinical observation in absence of palpable lymph nodes in high risk squamous cell carcinoma (CTR), 207
confocal microscopy of cutaneous neoplasms and normal skin (CTR), 318
dasatinib in locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery (CTR), 208
dasatinib in unresectable or metastatic squamous cell skin cancer or RAI stage 0-1 chronic lymphocytic leukemia (CTR), 207
early detection and cure in serial screening for melanoma, 244
FDA approves Gardasil to prevent anal cancer (PP), 325
FDA gives provisional approval to MelaFind device (PP), 1340
FDA panel votes in favor of MelaFind skin cancer detection device (PP), 213
imatinib in mucosal or acral/lentiginous melanoma (CTR), 208
lenalidomide in AIDS-related Kaposi sarcoma (CTR), 210
lessons from an exemplary physician in private setting (editorial), 238
liposomal daunorubicin in HIV-related Kaposi’s sarcoma (CTR), 212
melanoma detection by oblique-incidence optical spectroscopy (CTR), 318
melanoma in renal transplant patient (RR), 808
melanoma risk after other cancer diagnosis (NVR), 320
Merkel cell carcinoma as banal-appearing aggressive actor (NVR), 811
Mohs micrographic surgery for cutaneous lymphadenoma, 1324
new drug applications for vemurafenib in advanced skin cancer (PP), 805
novel devices for diagnosis and treatment, 21phase 2 trial of erlotinib prior to surgery or
radiation in squamous cell cancer of skin (CTR), 207
positive results in PLX4032 melanoma study (PP), 103
PTC299 in HIV-related Kaposi sarcoma (CTR), 211
regression of internal melanoma metastases after topical application of imiquimod (CR), 302
review of chemopreventative effects of oral retinoids for internal neoplasms, 1292
review of off-label clinical applications of imiquimod, 1300
second cancers after melanoma (NVR), 320sorafenib and temsirolimus in metastatic,
recurrent, or unresectable melanoma (CTR), 207
sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in hepatocellular carcinoma (CR), 308
spectral diagnosis of cutaneous malignancy (CTR), 318
study confirms sunscreen prevents melanoma (PP), 213
study evaluating two dose levels of Targretin
capsules in refractory cutaneous T-cell lymphoma (CTR), 209
study of ultrasonography with elastography in skin neoplasms (CTR), 319
in tattoo site, case of dermatofibrosarcoma protuberans and review of literature, 837
three-dimensional Mohs surgery, a new concept, 1273
trends in treatment and detection of skin cancer, 16
triage in Mohs micrographic surgery, 257ulcerated nodular nasal basal cell carcinoma
successfully treated with imiquimod 5% cream (letter to the editor), 240
use of gelatin sponges in Mohs micrographic surgery and staged melanoma excision, 68
winning poster: predictive factors for severity of scar formation after skin cancer surgeries (RS), 810
Nephrogenic systemic fibrosisalefacept therapy for (CR), 922case report and literature review (RR), 622
Neuroblastoma, review of chemopreventative effects of oral retinoids for, 1292
Neurofibromatosis, eruptive plexiform schwannomas in child with neurofibromatosis I (RR), 1210
Neurotoxins. See also Botulinum toxincosmeceutical and nutraceutical horizons, 24topical neurotoxin erases crow’s feet (PP),
1341Neutropenia, levamisole induced necrosis of skin
and neutropenia following intranasal cocaine use: a newly recognized syndrome (CR), 1204
News, Views and Reviews (NVR)biopsy diagnosis: clinical clues and patterns
to help distinguish cutaneous metastases, 678, 930
genes in psoriasis in 2011, where are we now?, 1337
manifestations and treatment of cutaneous lupus erythematosus, 1212, 1474
Merkel cell carcinoma as banal-appearing aggressive actor, 811
onychomycosis: is there a role for lasers, 1074second cancers after melanoma and
malignancies with risk for melanoma, 320
what’s new in androgenetic alopecia: approvals, long-term safety data, cancer risk, and treatment options for women, 98
what’s new in keloid treatment: new applications for common therapies, new treatments to come, 548
wound healing: from basic science to clinical practice and beyond, 427
Nitric oxide, taurine chloramine inhibits NO and TNF-a production in zymosan plus interferon-g activated RAW 264.7 cells, 659
Nitrogen, liquid, compared to dimethyl ether and propane in cryosurgical treatment of warts, case report and review of literature on, 1174
Nitroglycerin, FDA approval for Rectiv (PP), 939Non-steroidal anti-inflammatory agents,
cutaneous reactions to, 1160Notalgia paresthetica treatment with Xeomin
(CTR), 91Nova Southeastern University College of
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
Osteopathic Medicine and Broward General Medical Center Dermatology Residency Training Program
autoimmune-mediated blisters (for the Boards) (RR), 491
case report on pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545
program spotlight on (RR), 467Nutrition
cosmeceutical and nutraceutical horizons, 24phase 2 double-blind randomized placebo-
controlled trial of novel nutritional supplement product to promote health skin, 1106
randomized placebo-controlled double-blind study on efficacy of citrus bioflavanoid blend in senile purpura, 718
OOatmeal, colloidal, in atopic dermatitis and
other inflammatory skin diseases, s6 (September)
Oblique-incidence optical spectroscopy, melanoma detection by (CTR), 318
Oliveaesthetic benefits of natural ingredients in
skin care, s13 (September)evaluation of moisturizing effect of
methanolic extract incorporated into cream bases using impedance and extensiometry methods, 1116
OnabotulinumtoxinA (ONA)Allergan cell-based assay for BOTOX (PP), 938comparing clinical attributes of
abobotulinumtoxinA and ONA using Frontalis Rating Scale and Frontalis Activity Measurement Standard, 1148
FDA approves Botox for chronic migraine (PP), 104
in moderate-to-severe glabellar lines, rapid onset of response and patient-reported outcomes in, 39
Onychomycosisclinical evaluation of safety and efficacy of
new topical treatment for, 1186FDA clearance of PinPointe FootLaser for
(PP), 104role of lasers in (NVR), 1074
Optical coherence tomography, novel devices for diagnosis and treatment of skin disease, 21
Optical spectroscopy, oblique-incidence, melanoma detection by (CTR), 318
Oregano extract ointment, randomized double-blind petrolatum-controlled study on efficacy in wound healing, 1168
Organic products, use of term, s10 (September)Orthopedic implants, intralymphatic histiocytosis
associated with (RR), 1208Ovarian cancer, clinical clues and patterns
in biopsy diagnosis of cutaneous metastases of (NVR), 678, 930
Oxidative stressassessment of antioxidative capacity kinetics
of topical antioxidants, 262complementary antioxidant function of
caffeine and green tea polyphenols in normal human skin fibroblasts,
753green tea extract protects human skin
fibroblasts from reactive oxygen species induced necrosis, 1096
PPachyonychia congenita, small interfering RNAs
in, 28Pain management
in debridement of leg ulcers (PP), 324FDA approval of Rectiv for pain associated
with anal fissures (PP), 939novel 0.65 millisecond pulsed 1064 nm laser
to treat skin of color without skin cooling or anesthetics (DP), s10 (December)
Pediatric dermatologycomparing Cetaphil Restoraderm System
versus standard skin care in infants with atopic dermatitis (CTR), 1486
comparison of OTC moisturizer and prescription barrier creams in mild-to-moderate atopic dermatitis of children, 531
Epiduo pediatric acne study (CTR), 90, 312eruptive plexiform schwannomas in child with
neurofibromatosis I (RR), 1210metabolic syndrome and surrogate markers
of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900
new body moisturizer increases skin hydration and improves atopic dermatitis symptoms in children and adults, 714
novel KRT14 mutation in epidermolysis bullosa simplex with mottled pigmentation (CR), 926
pediatric longitudinal evaluation on long-term safety of Protopic Ointment for atopic dermatitis (CTR), 1217
pediatric vascular anomalies (RR), 893rituximab dosing in refractory pemphigus
vulgaris in adolescent male (CR), 202
safety and efficacy of LEO 80185 topical suspension in adolescents with scalp psoriasis (CTR), 95
scalp hyperkeratosis and alopecia in children of color, 511
XTRAC laser for psoriasis (PP), 938Peginterferon alfa-2b, FDA approves Sylatron to
treat melanoma (PP), 684Pemetrexed disodium and gemcitabine in
advanced mycosis fungoides or Sézary syndrome (CTR), 210
Pemphigoid, bullous, after herpes zoster vaccine administration (CR), 1328
Pemphigus foliaceus, fatal cutaneous strongyloidiasis as side effect of mycophenolate mofetil treatment in (CR), 418
Pemphigus vulgarisrandomized trial of intravenous
immunoglobulin with or without cyclophosphamide in (CTR), 1077
refractory, rituximab dosing in adolescent male (CR), 202
Perioral wrinkles, safety and effectiveness of small and large gel-particle hyaluronic acid in correction of, 982
Periorbital wrinkles, Taenda Luxe Device for home treatment of (PP), 1215
PH-10, Provectus Pharmaceuticals phase 2C clinical trial of PH-10 for psoriasis (PP), 806
Photoagingcomparison of retinol 1.0% and tretinoin
0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217
evaluation of prescription strength 4% hydroquinone/10% L-ascorbic acid treatment system for photodamage in normal to oily skin, 1455
multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352
multiplexed 1,440 and 1,320 nm fractionated laser for chronic photodamage, 1266
prospective randomized trial on effects of fluence settings in Er:YAG micropeel for facial photoaging, 179
safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
safety and efficacy of calcium hydroxylapatite for rejuvenation of aging hand, 47
Photodynamic therapy (PDT)effect of retinoid pretreatment on outcomes
of PDT for actinic keratosis of hand and forearm, 1124
in onychomycosis (NVR), 1074preliminary results of hidradenitis suppurativa
treatment with ALA-PDT, 381prospective case-based assessment of
sequential therapy with topical fluorouracil cream and ALA-PDT for actinic keratosis, 372
randomized blinded bilateral intraindividual vehicle-controlled trial of PDT with 5-aminolevulinic acid and blue light for actinic keratoses of upper extremities, 1049
safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
severe cutaneous reaction to PDT with blue light (CR), 1057
treatment of actinic cheilitis by ALA-PDT and blue light activation, 1240
treatment of actinic keratosis of face with imiquimod cream followed by (CTR), 426
trends in treatment of skin cancer, 17Photographs, importance of before and after
photographs to practice (DP), 940Photomedicine board review facts (RR), 750Photopheresis, efficacy of vorinostat in
combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sézary syndrome (BC), 403
Phototherapyadalimumab plus narrowband ultraviolet B
light phototherapy for moderate to severe psoriasis, 366
FDA approval of Syneron LED-based skin rejuvenation system (PP), 435
FDA grants marketing clearance for HairMax Dual 12 home-use laser phototherapy device (PP), 1341
histological and immunohistochemical evaluation of intense pulsed light photorejuvenation, 1246
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
promising future of laser and light therapy, 32randomized blinded bilateral intraindividual
vehicle-controlled trial of photodynamic therapy with 5-aminolevulinic acid and blue light for actinic keratoses of upper extremities, 1049
safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
self-treatment of mild-to-moderate facial acne with blue light treatment system, 596
severe cutaneous reaction to photodynamic therapy with blue light (CR), 1057
Taenda Luxe device for home treatment of periorbital wrinkles (PP), 1215
in transient porphyrinemia of neonate, purpura in (RR), 306
treatment of actinic cheilitis by photodynamic therapy with 5-aminolevulinic acid and blue light activation, 1240
XTRAC laser for psoriasis (PP), 938Pigmentation
comparative study of safety and efficacy of 75% mulberry extract oil versus placebo as topical treatment for melasma, 1025
comparison of 1% tretinoin peeling versus 70% glycolic acid peeling in female patients with melasma, 1439
effectiveness of topical tacrolimus for vitiligo in skin of color patients, 507
efficacy and safety of azelaic acid gel 15% in post-inflammatory hyperpigmentation and acne, 586
melasma in Latin Americans, 517natural therapies for hyperpigmentation, s11
(September), s15 (September)novel KRT14 mutation in epidermolysis
bullosa simplex with mottled pigmentation (CR), 926
pigmentary changes in patient treatment with imatinib (CR), 1062
pilot study using reflectance confocal microscopy in assessment of novel formulation for melasma, 1260
progressive macular hypomelanosis, 502Q-switched laser treatment of amiodarone
pigmentation (CR), 1316strategies minimizing irritation and iatrogenic
post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)
topical retinoids for pigmented skin, 483treating lentigines in Asian patients with
Q-switched Alexandrite laser (DP), s14 (December)
treatment of vitiligo with melanocyte-keratinocyte cell suspension versus dermabrasion only in pilot study with 12-month follow-up, 1032
Pimecrolimusbilateral comparison study of pimecrolimus
cream 1% and medical device cream in atopic dermatitis, 735
bilateral comparison study of pimecrolimus cream 1% and medical device emollient foam in atopic dermatitis, 666
Pipeline Previews (PP)Abbott files for 510(k) clearance for vitamin D
assay, 684Abbott withdraws briakinumab from FDA
review (PP), 435Acanya gel acne therapy available in pump,
1479Allergan cell-based assay for BOTOX, 938Alma Lasers introduces iPixel fractional
ablative technology, 805anakinra effective for severe Muckle-Wells
syndrome, 214Cardium Therapeutics announces FDA 510(k)
clearance for Excellagen, 1478Cleure launches FDA-approved broad-
spectrum sunscreen, 1076CoreRx Pharmaceuticals introduces
Xcelodose micro-dosing system, 1478
Crutchfield Dermatology now offers Selphyl wrinkle treatment, 213
Ellman International introduces Pellevé to European market, 938
EndyMed Medical receives FDA clearance for Fractional Skin Resurfacing Applicator, 435
Eucerin launches campaign in Europe and Asia, 1076
FDA approves Benlysta for lupus erythematosus, 806
FDA approves Botox for chronic migraine, 104FDA approves Ceftaroline for MRSA, 104FDA approves Fibrocell Science LAVIV, 939FDA approves first generic versions of
levofloxacin, 1076FDA approves Gardasil to prevent anal cancer,
325FDA approves Glenmark Generics mupirocin
2% ointment, 939FDA approves ipilimumab, 552FDA approves Natroba for head lice, 434FDA approves Rectiv (nitroglycerin) ointment,
939FDA approves Rituxan with corticosteroids for
severe vasculitis, 683FDA approves Sorilux (calcipotriene) foam,
103FDA approves Sylatron to treat melanoma,
684FDA approves Syneron LED-based skin
rejuvenation system, 435FDA approves Xeomin (incobotulinumtoxinA),
1076FDA approves Zyclara Cream 3.75% for
external genital warts, 552FDA bans skin whitening products containing
mercury, 1215FDA clearance of PinPointe FootLaser for nail
fungus, 104FDA gives provisional approval to MelaFind
device, 1340FDA grants clearance for HairMax Dual 12
home-use laser phototherapy device, 1341
FDA panel votes in favor of MelaFind skin cancer detection device, 213
FDA warming letter to Jaba Labs, 552Fibrocell Science, Inc. and azficel-T, 325, 939Genentech submits New Drug Application to
FDA, 1340Gly-Sal Acne Body Spray, 434Graceway receives FDA approval for Zyclara
Cream 2.5% for actinic keratosis, 1076
Helix Biopharma Corp. files clinical hold response on topical interferon alpha-2b, 1478
herpes zoster vaccine reduces zoster risk, 324
injection lipolysis of abdominal subcutaneous fat yields results, 103
La Roche-Posay introduces new products, 938LEO Pharma launches $0 copay program
for Taclonex plaque psoriasis treatments, 683
long-term efficacy and potencies of botulinum toxin A and B, 324
management of pain associated with debridement of leg ulcers, 324
methemoglobinemia risk from benzocaine topical products, 684
new analysis demonstrates activity in relapsed or refractory transformed mycosis fungoides, 213
New Drug Application for vemurafenib in advanced skin cancer, 805
New Drug Application for Yaupon’s mechlorethamine hydrochloride, 1478
nonablative 1927 nm fractional resurfacing for actinic keratoses, 103
positive results in advanced melanoma drug study, 103
Provectus Pharmaceuticals phase 2C clinical trial of PH-10 for psoriasis, 806
psoriasis drugs not linked to increased heart risks, 1215
Restylane for lip augmentation, 684resveratrol-containing gel for acne, 434ROGAINE introduces Unscented Topical Foam,
1076Safe Cosmetics Act of 2011, 1215Sagent Pharmaceuticals announces
FDA approval of bupivacaine hydrochloride injection, 1478
Sanuwave Health, Inc. dermaPACE device for diabetic foot ulcers, 325
solid hyaluronic acid tailored to fix fine wrinkles, 1341
Stiefel/GSK introduces Illumuminesse Brightening Complex, 938
study confirms sunscreen prevents melanoma, 213
Syneron devices at 22nd World Congress of Dermatology, 805
Taenda Luxe Device for home treatment of periorbital wrinkles, 1215
Taro receives FDA approval for imiquimod 5% cream, 683
topical neurotoxin erases crow’s feet, 1341Topix Pharmaceuticals, Inc. releases Replenix
ResurFIX Skin Barrier Healing Ointment, 805
XTRAC laser for psoriasis, 938Zelboraf (vemurafenib) receives FDA
approval, 1215PLX4032, positive results in melanoma study
(PP), 103Poly-L-lactic acid (PLLA), evolution of injectable
PLLA from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001
Polyacrylamide hydrogels, characteristics of different products, 1370
Polyangiitis, microscopic, FDA approval of Rituxan with corticosteroids for (PP), 683
Polyphenols, green teaaesthetic benefits of natural ingredients in
skin care, s12 (September)complementary antioxidant function of
caffeine and green tea polyphenols in normal human skin fibroblasts,
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
753Pomegranate, aesthetic benefits of natural
ingredients in skin care, s12 (September)
Porphyrinemia of neonate, transient, phototherapy-induced purpura in (RR), 306
Post-herpetic itch resolved with gabapentin (CR), 85
Post-inflammatory hyperpigmentationand acne in patients with skin of color, s13
(June)efficacy and safety of azelaic acid gel
15% in post-inflammatory hyperpigmentation and acne, 586
strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)
Povidone-iodine, chemical burn from (CR), 414Pralatrexate in Patients with Relapsed or
Refractory Peripheral T-Cell Lymphoma (PROPEL) (PP), 213
Prevention FDA approves Gardasil to prevent anal cancer
(PP), 325
review of chemopreventative effects of oral retinoids for internal neoplasms, 1292
study confirms sunscreen prevents melanoma (PP), 213
PROPEL (Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma) (PP), 213
Prurigo nodularis, CC-10004 for (CTR), 91Pruritus
acupressure for pruritus in atopic dermatitis (CTR), 90
CC-10004 for prurigo nodularis (CTR), 91efficacy, safety, and tolerability of topical
nalmefene for pruritus in atopic dermatitis, 853
efficacy of fluocinonide cream 0.1% in reducing itch in atopic dermatitis (CTR), 1486
post-herpetic itch resolved with gabapentin (CR), 85
randomized-withdrawal phase 3 study on safety and efficacy of nalfurafine HCl (AC-820) in hemodialysis and uremic pruritus (CTR), 91
treatment of notalgia paresthetica with Xeomin (CTR), 91
Pseudofolliculitis barbaebest practices and evidence-based use of 800
nm diode laser for pseudofolliculitis barbae in skin of color (DP), s20 (December)
safety and efficacy of laser hair removal in, 35Psoriasis
Abbott withdraws briakinumab from FDA review (PP), 435
adalimumab plus narrowband ultraviolet B light phototherapy for moderate to severe psoriasis, 366
assessment of national trends in acitretin treatment of, 873
association of depression with acitretin in, 409Bicillin-LA versus placebo for chronic plaque-
type psoriasis unresponsive to topical medications (CTR), 317
central serous chorioretinopathy associated with topical corticosteroids in (CR),
918CP-690-550 ointment for chronic plaque
psoriasis (CTR), 316diffuse large B-cell lymphoma associated with
biologic and other investigational agents in (CR), 80
dose finding study of AEB071 assessing psoriasis area and severity index in plaque psoriasis (CTR), 92
dose-ranging study of AIN457 in moderate-to-severe chronic plaque-type psoriasis (CTR), 93
efficacy and side effects of low-dose acitretin in (CTR), 95
FDA approval of Sorilux (calcipotriene) foam in (PP), 103
frequency of thrombocytopenia in tumor necrosis factor-a inhibitor treatment, 280
genes in (NVR), 1337impact of biologics on disease and treatment
burden of, 189increased prevalence of psychiatric disorders
and health care-associated costs in moderate-to-severe psoriasis, 843
LEO Pharma launches $0 copay program for Taclonex plaque psoriasis treatments (PP), 683
literature review on acitretin in, 772long-term study to evaluate safety and
tolerability of CP-690,550 in moderate-to-severe chronic plaque psoriasis (CTR), 94
metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900
multi-center open-label study on safety and efficacy of sequential treatment regimen of clobetasol propionate spray followed by calcitriol ointment in plaque psoriasis, 158
Mycobacterium fortuitum infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-a blockers (CR), 914
one-year study on efficacy and safety of CP-690,550 for moderate-to-severe chronic plaque psoriasis (CTR), 688
open-label prospective cohort pilot study on efficacy and safety of etanercept in moderate to severe plaque psoriasis in patients without adequate response to adalimumab, 396
Provectus Pharmaceuticals phase 2C clinical trial of PH-10 for psoriasis (PP), 806
psoriasis drugs not linked to increased heart risks (PP), 1215
randomized controlled trial on clobetasol propionate 0.05% spray for moderate-to-severe plaque psoriasis of scalp, 885
randomized study of PH-10 for (CTR), 315retrospective study of racial and ethnic
variations in psoriasis treatment with etanercept, 866
review of chemopreventative effects of oral retinoids for internal neoplasms in, 1292
review of infliximab treatment in 120 patients on therapy for a minimum of one year, 539
safety and efficacy of LEO 80185 topical suspension in adolescents with scalp psoriasis (CTR), 95
safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis (CTR), 1216
salicylic acid 6% in ammonium lactate emollient foam vehicle for scalp psoriasis, 270
study of clinical activity, safety, and tolerability of SRT2104 in moderate-to-severe plaque-type psoriasis (CTR), 92, 314
study of LY2439821 in moderate-to-severe psoriasis (CTR), 94
study to assess VB-201 in (CTR), 93, 316study to evaluate safety and effectiveness
of oral apremilast (CC-10004) in moderate-to-severe plaque psoriasis (CTR), 1487
study to explore efficacy and safety of ASP015K in moderate-to-severe psoriasis (CTR), 93, 315
T cell repertoire analysis of immune mediated skin diseases (CTR), 936
tattoo sites and (CR), 1199topical calcipotriene 0.005% and
betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in moderate-to-severe plaque psoriasis, 878
XTRAC laser for (PP), 938Yin-Yang strategy: proposing a new effective
repeatable sequential therapy for, 831
PSORS genes in psoriasis (NVR), 1337Psychiatric disorders, increased prevalence of
psychiatric disorders and health care-associated costs in moderate-to-severe psoriasis, 843
PTC299 in HIV-related Kaposi sarcoma (CTR), 211Pulsed dye laser
effects on scar formation (CTR), 96laser treatment of dyschromia with novel 607
nm pulsed-dye laser, 388treatment of surgical scars using (CTR), 96,
1216Purpura
phototherapy-induced, in transient porphyrinemia of neonate (RR), 306
randomized placebo-controlled double-blind study on efficacy of citrus bioflavanoid blend in senile purpura, 718
retiform, levamisole-induced (RR), 217Pyoderma gangrenosum
following breast reconstructive surgery, case report on treatment with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545
treatment with topical crushed dapsone (CR), 1059
QQ-switched laser treatment
of amiodarone pigmentation (CR), 1316treating lentigines in Asian patients with
Q-switched Alexandrite laser (DP), s14 (December)
QT intervals and QT dispersion, isotretinoin does not prolong QT intervals and QT
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
RRace/ethnicity
acne in patients with skin of color, s13 (June)advances in laser hair removal in skin of
color, 1235advances in treatment of keloids, 468best practices and evidence-based use of 800
nm diode laser for pseudofolliculitis barbae in skin of color (DP), s20 (December)
clinical pearls for dermal filler enhancement in patients with skin of color (DP), s23 (December)
community-based study of skin conditions and concerns in South Asian Americans (BC), 524
cosmetic treatments on skin of color, a unique challenge (editorial), s4 (December)
dermal fillers in skin of color, 494diode 810 nm laser as safe, effective modality
to meet a growing population need (DP), s8 (December)
effectiveness of topical tacrolimus for vitiligo in skin of color, 507
efficacy and safety of azelaic acid gel 15% in post-inflammatory hyperpigmentation and acne, 586
fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI (DP), s6 (December)
laser hair removal in ethnic skin, principles and practical aspects of (DP), s17 (December)
laser hair removal pearls in skin of color (DP), s12 (December)
melasma in Latin Americans, 517novel 0.65 millisecond pulsed 1064 nm laser
to treat skin of color without skin cooling or anesthetics (DP), s10 (December)
progressive macular hypomelanosis, 502retrospective study of racial and ethnic
variations in psoriasis treatment with etanercept, 866
safety and efficacy of cosmetic laser treatments for skin of color, 35
scalp hyperkeratosis and alopecia in children of color, 511
strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)
ten tips for acne vulgaris treatment in Fitzpatrick skin types IV–VI (BC), 654
topical retinoids for pigmented skin, 483treating lentigines in Asian patients with
Q-switched Alexandrite laser (DP), s14 (December)
Radiation therapyelectronic brachytherapy for non-melanoma
skin cancer treatment (CTR), 206phase 2 trial of erlotinib prior to surgery or
radiation in squamous cell cancer (CTR), 207
study of total skin electron beam therapy in stage IB-IIIA mycosis fungoides (CTR), 209
Radiofrequency device, multiple facial burns with new Thermage CPT system (CR), 1320
Radioiodine ablation of thyroid, iododerma
following (RR), 1070Rapamycin, recent advances and future directions
in medical management of skin disease, 28
RAW 264.7 cells, taurine chloramine inhibits NO and TNF-a production in zymosan plus interferon-g activated RAW 264.7 cells, 659
Reactive oxygen speciesassessment of kinetics of antioxidative
capacity of topical antioxidants, 262complementary antioxidant function of
caffeine and green tea polyphenols in normal human skin fibroblasts, 753
green tea extract protects human skin fibroblasts from reactive oxygen species induced necrosis, 1096
Reconstructive surgerycase report of pyoderma gangrenosum
following breast reconstructive surgery treated with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545
modified Tripier flap for lateral eyelid reconstruction (CR), 199
Red light source, safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
Reflectance confocal microscopy (RCM), pilot study using RCM in assessment of novel formulation for melasma, 1260
REGN668, sequential ascending dose study on safety and tolerability in atopic dermatitis (CTR), 314
Renal conditions. See KidneysResident Rounds (RR)
Albert Einsten College of Medicine Unified Division of Dermatology Residency Program program spotlight, 1122
autoimmune-mediated blisters (for the Boards), 491
case of trichomycosis axillaris and erythrasma, 1472
case report on pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and adjunctive xenogeneic matrix scaffolds, 545
cutaneous hypersensitivity during selective serotonin reuptake inhibitor therapy resulting in acquired cutis laxa, 215
dermal melanoma in transplant patient, 808Eastern Virginia Medical School Dermatology
Residency Program program spotlight, 344
erosive and desquamative syphilis associated with mucositis in setting of AIDS, 1335
eruptive plexiform schwannomas in child with neurofibromatosis I, 1210
fulminant dermatomyositis with flagellate erythema, 902
hair findings board review, 1464Harvard Combined Dermatology Residency
Training Program program spotlight, 186
high-yield dermatologic signs in Harvard Combined Residency Training Program, 197
highlights of common autoimmune connective tissue diseases, 1314
integrated basic and clinical sciences
conference, 1045intralymphatic histiocytosis associated with
orthopedic implants, 1208iododerma following radioactive iodine
ablation of thyroid for Graves disease, 1070
levamisole-induced retiform purpura, 217nephrogenic systemic fibrosis: case report
and literature review, 622noduloulcerative disease that still lingers after
all these centuries, 1072Nova Southeastern University College
of Osteopathic Medicine and Broward General Medical Center Dermatology Residency Training Program program spotlight, 467
pediatric vascular anomalies, 893photomedicine board review facts, 750phototherapy-induced purpura in transient
porphyrinemia of neonate, 306reported adverse effects of isotretinoin and
systemic corticosteroids, 287sound-alike and look-alike terms in
dermatology, 1196study aid: diagnosis and associations, 611ticks of dermatologic significance, 365University of California Davis Department of
Dermatology Residency Training Program program spotlight, 253
University of California Irvine Department of Dermatology Residency Training Program program spotlight, 593
University of California San Francisco Department of Dermatology Residency Training Program program spotlight, 883
University of Connecticut Dermatology Residency program spotlight, 1452
University of Louisville Dermatology Residency Training Program program spotlight, 1289
University of Massachusetts Medical School Dermatology Residency Program program spotlight, 716
University of Texas Southwestern Medical Center Dermatology Residency Program program spotlight, 1016
viral-associated trichodysplasia of immunosuppression in renal transplant patient, 422
Resident Spotlight (RS)comparison of diagnostic and biopsy/referral
sensitivity to melanoma between dermatologists and MelaFind, 1078
winning poster: phase 2 open-label investigator-initiated study of safety and efficacy of apremilast in recalcitrant contact or atopic dermatitis, 928
winning poster: predictive factors for severity of scar formation after skin cancer surgeries, 810
Resveratrol-containing gel for acne (PP), 434Retinoids
adapalene gel 0.3% in atrophic acne scars (CTR), 96
assessment of national trends in acitretin treatment of psoriasis, 873
in combination treatment for moderate-to-severe acne (CTR), 90
comparison of 1% tretinoin peeling versus 70% glycolic acid peeling in female patients with melasma, 1439
comparison of retinol 1.0% and tretinoin
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217
decrease of insulin growth factor-1 as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793
and depression, 409effect of retinoid pretreatment on outcomes
of photodynamic therapy for actinic keratosis of hand and forearm, 1124
Epiduo pediatric acne study (CTR), 90, 312isotretinoin does not prolong QT intervals
and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
literature review on acitretin in dermatology, 772
randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in acne vulgaris, 783
reported adverse effects of systemic corticosteroids and isotretinoin (RR), 287
rethinking treatment of acne in severe patient, s8 (June)
review of chemopreventative effects for internal neoplasms, 1292
safety and efficacy of micronized tretinoin 0.05% gel in adolescent acne, 647
study comparing Aczone plus Differin to Duac plus Differin in severe facial acne (CTR), 312
topical, for pigmented skin, 483in topical fixed-combination therapy and
topical monotherapy in acne, evidence-based review on, 636
Retinol, comparison of retinol 1.0% and tretinoin 0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217
Retinopathy, central serous chorioretinopathy associated with topical corticosteroids in psoriasis (CR), 918
Rheological evaluation of physical properties of hyaluronic acid dermal fillers, 974
commentary on (letter to the editor), 964Rhytids (rhytides). See WrinklesRituximab
dosing in refractory pemphigus vulgaris in adolescent male (CR), 202
FDA approval of Rituxan with corticosteroids for severe vasculitis (PP), 683
RNA, small interfering, in pachyonychia congenita, 28
Rosaceainflammation in rosacea and acne,
implications for patient care, 614investigator-blind randomized parallel-group
study on efficacy of novel rosacea treatment system, 1179
open label pilot study of Apremilast in (CTR), 313
papulopustular, self-reported treatment impressions and satisfaction of patients treated with doxycycline USP 40 mg capsules for, 1376
phase 3 efficacy and study of CD07805/47 topical gel in facial erythema associated with rosacea (CTR), 1216
vehicle formulations affecting efficacy, tolerability, and compliance with topical therapy, 627
Rose bengal, randomized study of PH-10 for psoriasis (CTR), 315
RT001, topical neurotoxin erases crow’s feet (PP), 1341
Rupatadine and levocetirizine in chronic idiopathic urticaria, comparative study of efficacy and safety, 1444
SSafe Cosmetics Act of 2011 (PP), 1215Safety issues
in blue versus red light sources for MAL-PDT in photodamaged skin, 53
in calcium hydroxylapatite rejuvenation of aging hand, 52-week study of, 47
clinical evaluation of safety and efficacy of new topical treatment for onychomycosis, 1186
clinical trial safety and mortality analysis of etanercept across approved indications, 289
comparative study of efficacy and safety of rupatadine and levocetirizine in chronic idiopathic urticaria, 1444
comparative study of safety and efficacy of 75% mulberry extract oil versus placebo as topical treatment for melasma, 1025
in comparison of cryotherapy and imiquimod for actinic keratoses, 1432
in cosmetic laser treatments for skin of color, 35
in dermal fillers in skin of color population, 494
diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis (CR), 80
diode 810 nm laser as safe, effective modality to meet a growing population need (DP), s8 (December)
dose-ranging study on safety and efficacy of IDP-107 in acne vulgaris (CTR), 426
double-blind randomized vehicle-controlled study on efficacy and safety of naftifine 2% cream in tinea cruris, 1142
double-blind randomized vehicle-controlled study on efficacy and safety of naftifine 2% cream in tinea pedis, 1282
efficacy, safety, and tolerability of SRD174 cream for pruritus in atopic dermatitis, 853
efficacy and safety of different concentrations of ZK245186 in atopic dermatitis (CTR), 313
hair regrowth following a Wnt- and follistatin-containing treatment, safety and efficacy in first-in-man phase 1 clinical trials, 1308
isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
in LEO 80185 topical suspension for adolescents with scalp psoriasis (CTR), 95
long-term study to evaluate safety and tolerability of CP-690,550 in moderate-to-severe chronic plaque psoriasis (CTR), 94
multi-center open-label study on safety and efficacy of sequential treatment regimen of clobetasol propionate spray followed by calcitriol ointment in plaque psoriasis, 158
one-year study on efficacy and safety of CP-690,550 for moderate-to-severe chronic plaque psoriasis (CTR), 688
open-label pilot study on effectiveness and safety of hyaluronic acid in lip augmentation, 145
open-label prospective cohort pilot study on efficacy and safety of etanercept in moderate to severe plaque psoriasis in patients without adequate response to adalimumab, 396
open-label study of safety and efficacy of sertaconazole nitrate in seborrheic dermatitis, 895
phase 3 efficacy and study of CD07805/47 topical gel in facial erythema associated with rosacea (CTR), 1216
phase 2 open-label investigator-initiated study of safety and efficacy of apremilast in recalcitrant contact or atopic dermatitis (RS), 928
safety and effectiveness of small and large gel-particle hyaluronic acid in correction of perioral wrinkles, 982
safety and efficacy of clindamycin phosphate 1.2%–benzoyl peroxide 3% fixed-dose combination gel for acne vulgaris, 1382
safety and efficacy of clobetasol propionate 0.05% emollient foam in alopecia (CTR), 1077
safety and efficacy of micronized tretinoin 0.05% gel in adolescent acne, 647
safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis (CTR), 1216
safety and efficacy study of bimatoprost in women with female pattern hair loss (CTR), 936
safety of tumescent and laser-assisted liposuction, review of literature on, 1363
safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis (CTR), 313, 687
sequential ascending dose study on safety and tolerability of REGN668 in atopic dermatitis (CTR), 314
study on clinical activity, safety, and tolerability of SRT2104 in moderate-to-severe plaque-type psoriasis (CTR), 92, 314
study on efficacy and safety of GDC-0449 in operable basal cell carcinoma (CTR), 206
study to evaluate safety and effectiveness of oral apremilast (CC-10004) in moderate-to-severe plaque psoriasis (CTR), 1487
study to explore efficacy and safety of ASP015K in moderate-to-severe psoriasis (CTR), 93, 315
Salicylic acidin ammonium lactate emollient foam vehicle
for scalp psoriasis, 270in Gly-Sal Acne Body Spray (PP), 434
Salmeterol xinafoate, injection lipolysis of abdominal subcutaneous fat yields results (PP), 103
Sarcoma, AIDS and HIV-related Kaposi sarcomalenalidomide in (CTR), 210liposomal daunorubicin in (CTR), 212PTC299 in (CTR), 211
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
Scalp cooling in prevention of chemotherapy-induced alopecia (CTR), 936
Scalp lesionslong-term complete sustained clearance of
actinic keratoses of face or balding scalp after imiquimod treatment, 95
randomized controlled trial on clobetasol propionate 0.05% spray for moderate-to-severe plaque psoriasis of scalp, 885
safety and efficacy of LEO 80185 topical suspension in adolescents with scalp psoriasis (CTR), 95
salicylic acid 6% in ammonium lactate emollient foam vehicle for scalp psoriasis, 270
scalp hyperkeratosis and alopecia in children of color, 511
Scars/scarringadapalene gel in treatment of atrophic acne
scars (CTR), 96burn scar appearance after fractional carbon
dioxide laser treatment (CTR), 96effects of pulsed-dyed laser on scar formation
(CTR), 96evaluation of clinical improvement in acne
scars and active acne in 1540-nm non-ablative fractional laser treatment, 907
fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI (DP), s6 (December)
multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352
treatment of surgical scars using pulsed dye laser (CTR), 96, 1216
winning poster: predictive factors for severity of scar formation after skin cancer surgeries (RS), 810
Schwannoma, eruptive plexiform, in child with neurofibromatosis I (RR), 1210
Screening, early detection and cure of melanoma in serial screening, 244
Seborrheic dermatitis, open-label study of safety and efficacy of sertaconazole nitrate in, 895
Secukinumab, safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis (CTR), 1216
Serotonin reuptake inhibitor therapy, selective, cutaneous hypersensitivity to resulting in acquired cutis laxa (RR), 215
Sertaconazole nitrateopen-label study of safety and efficacy in
seborrheic dermatitis, 895treatment of interdigital tinea pedis with
once-daily therapy with, 1135Sézary syndrome. See Mycosis fungoides/Sézary
syndromeSkin barrier function
clinical relevance of maintaining structural and functional integrity of stratum corneum, s5 (October)
comparison of OTC moisturizer and prescription barrier creams in mild-to-moderate atopic dermatitis of children, 531
effects of novel fluocinonide cream formulation on, in atopic dermatitis, 171
managing epidermal barrier function in treatment of dermatoses, s13
(October)new body moisturizer increases skin
hydration and improves atopic dermatitis symptoms in children and adults, 744
role of stratum corneum in healthy and diseased skin (editorial), s4 (October)
Topix Pharmaceuticals, Inc. releases Replenix ResurFIX Skin Barrier Healing Ointment (PP), 805
Skin cancercancer: this war is personal (editorial), 237clinical trial of Dermacorder for detecting
malignant skin lesions (CTR), 317comparison of diagnostic and biopsy/referral
sensitivity to melanoma between dermatologists and MelaFind (RS), 1078
comparison of elective lymph node treatment versus clinical observation in absence of palpable lymph nodes in high risk squamous cell carcinoma (CTR), 207
confocal microscopy of cutaneous neoplasms and normal skin (CTR), 318
dasatinib in locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery (CTR), 208
dasatinib in unresectable or metastatic squamous cell skin cancer or RAI stage 0-1 chronic lymphocytic leukemia (CTR), 207
dermal melanoma in renal transplant patient (RR), 808
early detection and cure in serial screening for melanoma, 244
electronic brachytherapy for non-melanoma skin cancer treatment (CTR), 206
eruptive squamous cell carcinoma with keratoacanthoma-like features in sorafenib treatment (CR), 308
FDA gives provisional approval to MelaFind device (PP), 1340
FDA panel votes in favor of MelaFind skin cancer detection device (PP), 213
imatinib in mucosal or acral/lentiginous melanoma (CTR), 208
lessons from an exemplary physician in private setting (editorial), 238
Merkel cell carcinoma as banal-appearing aggressive actor (NVR), 811
Mohs micrographic surgery for cutaneous lymphadenoma (CR), 1324
new drug applications for vemurafenib in advanced skin cancer (PP), 805
novel devices for diagnosis and treatment, 21phase 2 trial of erlotinib prior to surgery or
radiation in (CTR), 207sorafenib and temsirolimus in metastatic,
recurrent, or unresectable melanoma (CTR), 207
spectral diagnosis of cutaneous malignancy (CTR), 318
study confirms sunscreen prevents melanoma (PP), 213
study of ultrasonography with elastography in skin neoplasms (CTR), 319
study on efficacy and safety of GDC-0449 in operable basal cell carcinoma (CTR), 206
three-dimensional Mohs surgery, a new concept, 1273
trends in treatment and detection of, 16triage in Mohs micrographic surgery, 257ulcerated nodular nasal basal cell carcinoma
successfully treated with imiquimod 5% cream (letter to the editor), 240
unresectable or metastatic, dasatinib in (CTR), 207
use of gelatin sponges in Mohs micrographic surgery and staged melanoma excision, 68
winning poster: predictive factors for severity of scar formation after skin cancer surgeries (RS), 810
Skin Health Experimental Product (SHEP), phase 2 double-blind randomized placebo-controlled trial of novel nutritional supplement product to promote healthy skin, 1106
Skin lightening productsFDA ban on skin whitening products
containing mercury (PP), 1215natural therapies for hyperpigmentation, s11
(September), s15 (September)Skin of color
acne in patients with, s13 (June)advances in laser hair removal in, 1235advances in treatment of keloids, 468best practices and evidence-based use of 800
nm diode laser for pseudofolliculitis barbae in skin of color (DP), s20 (December)
clinical pearls for dermal filler enhancement in patients with skin of color (DP), s23 (December)
community-based study of skin conditions and concerns in South Asian Americans (BC), 524
cosmetic treatments on skin of color, a unique challenge (editorial), s4 (December)
dermal fillers in, 494diode 810 nm laser as safe, effective modality
to meet a growing population need (DP), s8 (December)
effectiveness of topical tacrolimus for vitiligo in, 507
efficacy and safety of azelaic acid gel 15% in post-inflammatory hyperpigmentation and acne, 586
fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI (DP), s6 (December)
laser hair removal in ethnic skin, principles and practical aspects of (DP), s17 (December)
laser hair removal pearls in skin of color (DP), s12 (December)
melasma in Latin Americans, 517novel 0.65 millisecond pulsed 1064 nm laser
to treat skin of color without skin cooling or anesthetics (DP), s10 (December)
progress made, challenges remain (editorial), 459
progressive macular hypomelanosis, 502retrospective study of racial and ethnic
variations in psoriasis treatment with etanercept, 866
safety and efficacy of cosmetic laser treatments for, 35
scalp hyperkeratosis and alopecia in children of color, 511
strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with (DP), s25 (December)
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
ten tips for acne vulgaris treatment in Fitzpatrick skin types IV–VI (BC), 654
topical retinoids for pigmented skin, 483Skin resurfacing
EndyMed Medical receives FDA clearance for Fractional Skin Resurfacing Applicator (PP), 435
nonablative 1927 nm fractional resurfacing for actinic keratoses (PP), 103
safety and efficacy of cosmetic laser treatments for skin of color, 37
Sodium sulfacetamide-sulfur in topical rosacea therapy, vehicle formulations for, 627
Sodium thiosulfate, topical sodium thiosulfate 25% treatment for ulcerative calcinosis cutis, 1042
Soft tissue augmentationcombined treatment for skin rejuvenation and
soft-tissue augmentation of aging face, 125
management of impending necrosis associated with soft tissue filler injections (CR), 1007
Sorafenibchloracne-like drug eruption associated with
(CR), 1331eruptive squamous cell carcinomas with
keratoacanthoma-like features in patients treated with (CR), 308
erythema multiforme-like drug reaction to (CR), 1462
and temsirolimus in metastatic, recurrent, or unresectable melanoma (CTR), 207
Sound-line and look-alike terms in dermatology (RR), 1196
South Asian Americans, community-based study of skin conditions and concerns in (BC), 524
Soy productsaesthetic benefits of natural ingredients in
skin care, s11 (September)for hyperpigmentation, s16 (September)
Spectral diagnosis of cutaneous malignancy (CTR), 318
Spinosad, FDA approves Natroba for head lice (PP), 434
Spironolactoneadvantages of oral contraceptives and
spironolactone for women with acne (DP), 941
in female androgenetic alopecia (NVR), 100Squamous cell carcinoma (SCC)
comparison of elective lymph node treatment versus clinical observation in absence of palpable lymph nodes in high risk SCC (CTR), 207
dasatinib in unresectable or metastatic squamous cell skin cancer or RAI stage 0-1 chronic lymphocytic leukemia (CTR), 207
electronic brachytherapy for treatment of (CTR), 206
eruptive, with keratoacanthoma-like features in sorafenib treatment (CR), 308
phase 2 trial of erlotinib prior to surgery or radiation in (CTR), 207
SRD174 cream, efficacy, safety, and tolerability of SRD174 cream for pruritus in atopic dermatitis, 853
SRT2104, study of clinical activity, safety, and tolerability in moderate-to-severe plaque-type psoriasis (CTR), 92, 314
Staphylococcus aureus, FDA approves Ceftaroline for MRSA (PP), 104
START (Swiss Taxotere Alopecia Prevention Trial) (CTR), 936
Stevens-Johnson syndrome, short-term and low-dose oral fluconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients (letter to the editor), 1360
Stoma site, treatment of peristomal pyoderma gangrenosum with topical crushed dapsone (CR), 1059
Stomach cancer, clinical clues and patterns in biopsy diagnosis of cutaneous metastases (NVR), 678, 930
Stratum corneumclinical relevance of maintaining structural
and functional integrity of, s5 (October)
managing epidermal barrier function in treatment of dermatoses, s13 (October)
role in healthy and diseased skin (editorial), s4 (October)
Striae, multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352
Strongyloidiasis, fatal cutaneous, as side effect of mycophenolate mofetil in pemphigus foliaceus (CR), 418
SunscreensCleure launches FDA-approved broad-
spectrum sunscreen (PP), 1076impact of natural sunlight exposure on UVB-
SPF and UVA-PF of UVA/UVB SPF 50 sunscreen, 150
in novel rosacea treatment system, investigator-blind randomized parallel-group study on, 1179
study confirms sunscreen prevents melanoma (PP), 213
Swiss Taxotere Alopecia Prevention Trial (START) (CTR), 936
Syphiliserosive and desquamative, associated with
mucositis in setting of AIDS (RR), 1335
and lues maligna in HIV infection (RR), 1072
TT cell(s)
CD70 and Th17 involvement in human contact sensitivity (BC), 1192
repertoire analysis of immune mediated skin diseases (CTR), 936
T cell leukemia/lymphoma, adult (ATLL), vesiculobullous variant in Caribbean émigré (CR), 1469
T cell lymphomaPralatrexate in Patients with Relapsed
or Refractory Peripheral T-Cell Lymphoma (PROPEL) (PP), 213
review of chemopreventative effects of oral retinoids for cutaneous T cell lymphoma, 1292
study evaluating two dose levels of Targretin capsules in refractory cutaneous T cell lymphoma (CTR), 209
Tacrolimus, topical, effectiveness for vitiligo in skin of color, 507
Tamoxifen-induced hirsutism (CR), 799Tattoos
malignancy arising within, case of dermatofibrosarcoma protuberans and review of literature, 837
and psoriasis (CR), 1199topical imiquimod with Nd:YAG laser for
removal of (CTR), 1342Taurine chloramine inhibits NO and TNF-a
production in zymosan plus interferon-g activated RAW 264.7 cells, 659
Tazaroteneeffect of retinoid pretreatment on outcomes
of photodynamic therapy for actinic keratosis of hand and forearm, 1124
randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in acne vulgaris, 783
in topical monotherapy for acne, compared to fixed-combination therapy, 636
Temporal fossa augmentation with small gel particle hyaluronic acid dermal filler, 673
Temsirolimus and sorafenib in metastatic, recurrent, or unresectable melanoma (CTR), 207
Tetanus, diphtheria and pertussis vaccination, case of lichen planus following (CR), 1067
Tetrahydroxypropyl ethylenediamine (THPE), clinical evidence for activity of THPE as new anti-aging active cosmetic, 1102
Thalidomide, and complement activation by Mycobacterium leprae, 274
Thermage CPT system, multiple facial burns with (CR), 1320
Thrombocytopenia in tumor necrosis factor-a inhibitor therapy for psoriasis, frequency of, 280
Thyroidclinical clues and patterns in biopsy diagnosis
of cutaneous metastases of thyroid cancer (NVR), 678, 930
iododerma following radioactive iodine ablation of thyroid for Graves disease (RR), 1070
Ticks of dermatologic significance (RR), 365Tinea cruris, double-blind randomized vehicle-
controlled study on efficacy and safety of naftifine 2% cream in, 1142
Tinea pedisonce-daily therapy with sertaconazole nitrate
for, 1135randomized double-blind vehicle-controlled
efficacy and safety study of naftifine 2% cream in, 1282
Total skin electron beam therapy (TSEBT) in stage IB-IIIA mycosis fungoides (CTR), 209
Tower technique for injection of hyaluronic acid fillers, 1277
TrainingAlbert Einsten College of Medicine Unified
Division of Dermatology Residency Program (RR), 1122, 1196, 1208
autoimmune-mediated blisters (for the Boards) (RR), 491
CME: demystifying acne algorithms, s5 (June), s24 (June), s26 (June)
CME: identifying natural ingredients and their use in skin care, s4 (September), s21 (September), s22 (September)
Eastern Virginia Medical School Dermatology Residency Program (RR), 344, 365, 422
hair findings board review (RR), 1464Harvard Combined Dermatology Residency
Training Program (RR), 186, 197high yield dermatologic signs (RR), 197highlights of common autoimmune
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
connective tissue diseases (RR), 1314
integrated basic and clinical sciences conference (RR), 1045
nanotechnology and dermatology education in United States, data from pilot survey, 1037
Nova Southeastern University College of Osteopathic Medicine and Broward General Medical Center Dermatology Residency Training Program (RR), 467, 491, 545
pediatric vascular anomalies (RR), 893photomedicine board review facts (RR), 750sound-alike and look-alike terms in
dermatology (RR), 1196study aid: diagnosis and associations (RR),
611University of California Davis Department of
Dermatology Residency Training Program (RR), 253, 287, 306
University of California Irvine Department of Dermatology Residency Training Program (RR), 593, 611, 622
University of California San Francisco Department of Dermatology Residency Training Program (RR), 883, 893, 902
University of Connecticut School of Medicine Dermatology Residency (RR), 1452, 1464, 1472
University of Louisville School of Medicine Dermatology Residency Training Program (RR), 1289, 1314, 1335
University of Massachusetts Medical School Dermatology Residency Program (RR), 716, 750, 808
University of Texas Southwestern Medical Center Dermatology Residency Program (RR), 1016, 1045, 1070, 1072
Transepidermal water losseffects of novel fluocinonide cream
formulation on skin barrier function in atopic dermatitis, 171
new body moisturizer increases skin hydration and improves atopic dermatitis symptoms in children and adults, 744
Transplant recipientsmelanoma in renal transplant patient (RR),
808viral-associated trichodysplasia of
immunosuppression in renal transplant patient (RR), 422
Tretinoinin combination treatment for moderate-to-
severe acne (CTR), 90comparison of 1% tretinoin peeling versus
70% glycolic acid peeling in female patients with melasma, 1439
comparison of retinol 1.0% and tretinoin 0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217
safety and efficacy of micronized tretinoin 0.05% gel in adolescent acne, 647
in topical monotherapy for acne, compared to fixed-combination therapy, 636
Triage in Mohs micrographic surgery, 257Trichodysplasia of immunosuppression, viral-
associated, in renal transplant patient (RR), 422
Trichomycosis axillaris, and erythrasma, case of (RR), 1472
Tripier flap, modified, for lateral eyelid reconstruction (CR), 199
Triple compression bandage and chitosan gel in treatment of venous leg ulcers, 75
Tumeric, aesthetic benefits of natural ingredients in skin care, s12 (September)
Tumescent liposuction, safety of tumescent and laser-assisted liposuction, review of literature on, 1363
Tumor necrosis factor-aadalimumab plus narrowband ultraviolet B
light phototherapy for moderate to severe psoriasis, 366
clinical trial safety and mortality analysis in patients receiving etanercept across approved indications, 289
etanercept as sole treatment for grade I acute graft versus host disease (CTR), 1487
frequency of thrombocytopenia in psoriasis treated with tumor necrosis factor-a inhibitors, 280
Mycobacterium fortuitum infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-a blockers (CR), 914
open-label prospective cohort pilot study on efficacy and safety of etanercept in moderate to severe plaque psoriasis in patients without adequate response to adalimumab, 396
retrospective study of racial and ethnic variations in psoriasis treatment with etanercept, 866
review of infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year, 539
safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis (CTR), 1216
taurine chloramine inhibits NO and TNF-a production in zymosan plus interferon-g activated RAW 264.7 cells, 659
topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in moderate-to-severe plaque psoriasis, 878
treatment of recalcitrant generalized granuloma annulare with adalimumab (CR), 1466
Tyrosinase, asethetic benefits of natural ingredients in skin care, s11 (September)
Tyrosinase inhibitors, asethetic benefits of natural ingredients in skin care, s11 (September)
UUlcers
dermaPACE device for diabetic foot ulcers (PP), 325
novel treatment for ulcerative calcinosis cutis, 1042
pain management in debridement of leg ulcers (PP), 324
Topix Pharmaceuticals releases Replenix ResurFIX Skin Barrier Healing Ointment (PP), 805
treatment efficacy of triple bandage compression and chitosan gel in
venous leg ulcers, 75ulcerated nodular nasal basal cell carcinoma
successfully treated with imiquimod 5% cream (letter to the editor), 240
Ultrasonography with elastography in skin neoplasms (CTR), 319
Ultraviolet (UV) radiation exposureadalimumab plus narrowband UV B light
phototherapy for moderate to severe psoriasis, 366
assessment of antioxidative capacity kinetics of topical antioxidants in, 262
Cleure launches FDA-approved broad-spectrum sunscreen (PP), 1076
complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts, 753
evaluation of prescription strength 4% hydroquinone/10% L-ascorbic acid treatment system for photodamage in normal to oily skin, 1455
impact on UVB-SPF and UVA-PF of UVA/UVB SPF 50 sunscreen, 150
in keloids (NVR), 550multiplexed 1,440 and 1,320 nm fractionated
laser for chronic photodamage, 1266
Unified Division of Dermatology of Albert Einstein College of Medicine
eruptive plexiform schwannomas in child with neurofibromatosis I (RR), 1210
intralymphatic histiocytosis associated with orthopedic implants (RR), 1208
program spotlight on Residency Program (RR), 1122
sound-alike and look-alike terms in dermatology (RR), 1196
University of California–Davisphototherapy-induced purpura in transient
porphyrinemia of neonate (RR), 306program spotlight on Department of
Dermatology Residency Training Program (RR), 253
reported adverse effects of isotretinoin and systemic corticosteroids (RR), 287
University of California–Irvinenephrogenic systemic fibrosis: case report
and literature review (RR), 622program spotlight on Dermatology Residency
Training Program (RR), 593study aid: diagnosis and associations (RR),
611University of California–San Francisco
fulminant dermatomyositis with flagellate erythema (RR), 902
pediatric vascular anomalies (RR), 893program spotlight on Department of
Dermatology Residency Training Program (RR), 883
University of Connecticut School of Medicinecase of trichomycosis axillaris and erythrasma
(RR), 1472hair findings board review (RR), 1464program spotlight on Dermatology Residency
(RR), 1452University of Louisville School of Medicine
erosive and desquamative syphilis associated with mucositis in setting of AIDS (RR), 1335
highlights of common autoimmune connective tissue diseases (RR), 1314
program spotlight on Dermatology Residency
Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology
SU
BJE
CT
IND
EX
Training Program (RR), 1289University of Massachusetts Medical School
dermal melanoma in transplant patient (RR), 808
photomedicine board review facts (RR), 750program spotlight on Dermatology Residency
Program (RR), 716University of Texas Southwestern Medical Center
integrated basic and clinical sciences conference (RR), 1045
iododerma following radioactive iodine ablation of thyroid for Graves disease (RR), 1070
noduloulcerative disease that still lingers after all these centuries (RR), 1072
program spotlight on Dermatology Residency Program (RR), 1016
Urticariachronic, treatment with colchicine, 1423chronic idiopathic, comparative study of
efficacy and safety of rupatadine and levocetirizine in, 1444
drug-induced, causes and clinical courses of, 1019
VVaccines
bullous pemphigoid after herpes zoster vaccine administration (CR), 1328
case of lichen planus following Tdap vaccination (CR), 1067
FDA approves Gardasil to prevent anal cancer (PP), 325
herpes zoster vaccine reduces zoster risk (PP), 324
Vascular anomalies, pediatric (RR), 893Vasculitis, FDA approval of Rituxan with
corticosteroids for (PP), 683VB-201, study to assess in psoriasis (CTR), 93, 316Vehicle formulations
in topical acne therapy, importance of, s17 (June)
in topical rosacea therapy, affecting efficacy, tolerability, and compliance, 627
Vemurafenibnew drug applications for vemurafenib in
advanced skin cancer (PP), 805Zelboraf receives FDA approval (PP), 1215
Venous leg ulcers, treatment efficacy of triple bandage compression and chitosan gel in, 75
Vismodegib, Genentech submits New Drug Application to FDA (PP), 1340
Vitamin DAbbott files for 510(k) clearance for vitamin D
assay (PP), 684in keloids (NVR), 550multi-center open-label study on safety and
efficacy of sequential treatment regimen of clobetasol propionate spray followed by calcitriol ointment in plaque psoriasis, 158
Vitiligo vulgarisin skin of color, effectiveness of topical
tacrolimus treatment in, 507treatment with melanocyte-keratinocyte cell
suspension versus dermabrasion only in pilot study with 12-month follow-up, 1032
Vorinostat, efficacy in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sézary syndrome (BC), 403
WWarts
comparison of dimethyl ether and propane to liquid nitrogen in cryosurgical treatment of, case report and review of literature on, 1174
FDA approves Zyclara Cream 3.75% for external genital warts (PP), 552
metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900
Wegener’s granulomatosis, FDA approval of Rituxan with corticosteroids for (PP), 683
Wnt, hair regrowth following a Wnt- and follistatin-containing treatment, safety and efficacy in first-in-man phase 1 clinical trials, 1308
World Congress of Dermatology, Syneron devices introduced at (PP), 805
Wound healingfrom basic science to clinical practice and
beyond (NVR), 427Cardium Therapeutics announces FDA 510(k)
clearance for Excellagen (PP), 1478case report of pyoderma gangrenosum
following breast reconstructive surgery treated with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545
randomized double-blind petrolatum-controlled study on efficacy of oregano extract ointment in, 1168
secondary, in use of gelatin sponges in Mohs micrographic surgery defects and staged melanoma excisions, 68
Topix Pharmaceuticals releases Replenix ResurFIX Skin Barrier Healing Ointment (PP), 805
treatment efficacy of triple bandage compression and chitosan gel in venous leg ulcers, 75
winning poster: predictive factors for severity of scar formation after skin cancer surgeries (RS), 810
Wrinklesazficel-T in nasolabial folds and wrinkles (PP),
325, 939comparing clinical attributes of
abobotulinumtoxinA and onabotulinumtoxinA using Frontalis Rating Scale and Frontalis Activity Measurement Standard, 1148
comparison of retinol 1.0% and tretinoin 0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217
corrugator supercilii muscle terminal nerve ablation using novel thread technique for treatment of hyperdynamic vertical glabellar furrows, 762
Crutchfield Dermatology now offers Selphyl wrinkle treatment (PP), 213
efficacy and tolerability of new monophasic double-crosslinked hyaluronic acid filler for deep lines and, 134
efficacy of cream-based novel formulations of hyaluronic acid of different molecular weights in anti-wrinkle treatment, 990
Ellman International introduces Pellevé Wrinkle Reduction System to European market (PP), 938
FDA approval for Syneron LED-based skin rejuvenation system (PP), 435
FDA approval of Xeomin (incobotulinumtoxinA) for glabellar lines (PP), 1076
histological and immunohistochemical evaluation of intense pulsed light photorejuvenation for, 1246
La Roche-Posay introduces new products (PP), 938
multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352
rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines, 39
safety and effectiveness of small and large gel-particle hyaluronic acid in correction of perioral wrinkles, 982
safety and efficacy of calcium hydroxylapatite for rejuvenation of aging hand, 47
solid hyaluronic acid tailored to fix fine wrinkles (PP), 1341
Taenda Luxe Device for home treatment of periorbital wrinkles (PP), 1215
topical neurotoxin erases crow’s feet (PP), 1341
tower technique for injection of hyaluronic acid fillers in, 1277
WS-1 fibroblast cells, complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts, 753
ZZanolimumab, study of human monoclonal
antibody to treat mycosis fungoides and Sézary syndrome (CTR), 1077
Zincand copper in natural therapies for
hyperpigmentation, s18 (September)
randomized double-blind placebo-controlled multi-center trial of zinc for herpes simplex labialis, 1343
ZK245186 in atopic dermatitis, efficacy and safety of different concentrations (CTR), 313
Zoster, herpes zoster vaccine reduces zoster risk (PP), 324
Zymosan, taurine chloramine inhibits NO and TNF-a production in zymosan plus interferon-g activated RAW 264.7 cells, 659